PCT

(22) International Filing Date:

60/054,268

65211 (US).

(30) Priority Data:

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:		(11) International Publication Number: WO 99/06571
C12N 15/53, 15/82, 15/81, 9/06, 1/21, 1/19, 5/10, A01H 5/00, C12Q 1/26	A1	(43) International Publication Date: 11 February 1999 (11.02.99)
(21) International Application Number: PCT/US	98/158	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE,

US

US

30 July 1998 (30.07.98)

29 July 1998 (29.07.98) 09/124,541 (71) Applicant: THE CURATORS OF THE UNIVERSITY OF MISSOURI [US/US]; 509 Lewis Hall, Columbia, MO

30 July 1997 (30.07.97)

(72) Inventor: MORRIS, Roy, O.; 4938 Bethel Street, Columbia, MO 65203 (US).

(74) Agents: BLOSSER, G., Harley et al.; Senniger, Powers, Leavitt & Roedel, 16th floor, One Metropolitan Square, St. Louis, MO 63102 (US).

GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: CYTOKININ OXIDASE

(57) Abstract

An isolated protein which exhibits cytokinin oxydizing activity selected from the group consisting of SEQ. ID No. 1, a protein having an amino acid sequence which includes the amino acid sequence of SEQ. ID No. 1, a protein having an amino acid sequence which includes a portion of the amino acid sequence of SEQ. ID No. 1, the included portion being at least about 20 amino acid residues in length and conferring the cytokinin oxidizing activity on the protein, and a protein including an amino acid sequence with at least about 65 % sequence identity to SEQ. ID No. 1, the remainder of amino acid residues being conservatively substituted. Nucleic acids encoding proteins which exhibit cytokinin oxidizing activity and related products and methods are also disclosed.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL AM	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AT	Armenia	FI	Finland	LT	Lithuania	sk	Slovakia
	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
Z	Azerbaijan	GB	United Kingdom	MC	Моласо	TD	
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Chad
B	Barbados	GH	Ghana	MG	Madagascar		Togo
B	Belgium	GN	Guinea	MK	The former Yugoslav	TJ	Tajikistan
F	Burkina Faso	GR	Greece	17425	Republic of Macedonia	TM	Turkmenistan
G	Bulgaria	HU	Hungary	ML	Mali	TR	Turkey
IJ	Benin	IE	Ireland	MN		TT	Trinidad and Tobago
R	Brazil	IL	Israel	MR	Mongolia	UA	Ukraine
Y	Belarus	IS	Iceland		Mauritania	UG	Uganda
:A	Canada	IT	Italy	MW	Malawi	US	United States of Ameri
F	Central African Republic	JP	Japan	MX	Mexico	UZ	Uzbekistan
G	Congo	KE	Kenya	NE	Niger	VN	Vict Nam
H	Switzerland	KG	The state of the s	NL	Netherlands	YU	Yugoslavia
1	Côte d'Ivoire	KP	Kyrgyzstan	NO	Norway	zw	Zimbabwe
M	Cameroon	N.P	Democratic People's	NZ	New Zealand		
N	China	7/D	Republic of Korea	PL	Poland		
U	Cuba	KR	Republic of Korea	PT	Portugal	•	
Z	Czech Republic	KZ	Kazakstan	RO	Romania		
E		rc	Saint Lucia	RU	Rustian Federation		
K	Germany	L	Liechtenstein	SD	Sudan		=
	Denmark	LK.	Sri Lanka	SE	Sweden		•
Œ	Batonia	LR	Liberia	SG	Singapore		

WO 99/06571 PCT/US98/15844

CYTOKININ OXIDASE

BACKGROUND OF THE INVENTION

5

10

The present invention relates to a purified plant cytokinin oxidizing enzyme (ckx1) from Zea mays, the complete amino acid sequence of which has been elucidated, and to isolated nucleotide sequences encoding the enzyme. The invention further relates to novel methods for moderating the concentration of the enzyme and similar enzymes in plants in order to affect plant cell growth and death. Applications of the invention include the regulation of the production of ckx1 in plant roots to affect pathogenesis, the regulation to alter plant habit, and the bulk production of ckx1 enzyme for use in a plant biochemical assay.

Plant cytokinins are a class of plant hormones which, when combined with auxin, control cell division, 15 promote shoot development from callus, release lateral buds from dormancy, and regulate plant structure and growth in a variety of ways. The naturally occurring active cytokinins in most higher plants are free-base zeatin (6-(4-hydroxy-3-methylbut-trans-2-20 enylamino)purine) (hereinafter Z), and its 9-riboside (hereinafter ZR). Plant tissues normally contain, therefore, Z, ZR, and smaller amounts of N^6 - $(\Delta^2$ isopentenyl) adenine (hereinafter, iP) derived from biosynthetic precursors. Elevated cytokinin levels are 25 associated with the development of seeds in higher plants, and have been demonstrated to coincide with maximal mitotic activity in the endosperm of developing maize kernels and other cereal grains. Exogenous cytokinin application (via stem injection) has been shown 30 to directly correlate with increased kernel yield in maize. In addition, plant cells transformed with the ipt gene from Agrobacterium tumefaciens (encoding a

25

dimethylallylpyrophosphate:5'-AMP transferase capable of increasing cellular production of Z and ZR) showed increased growth corresponding to an increase in endogenous cytokinin levels upon induction of the enzyme. Thus, given the biosignificance of cytokinins to the growth of plants, the ability to manipulate cytokinin levels in higher plant cells is of great commercial and scientific interest.

The action of cytokinin oxidase is a major method of effective cytokinin catabolism in plant cells. This inactivation of cytokinin is accomplished by the oxidative removal of the side chain from cytokinin free bases (or their ribosides) in the presence of molecular oxygen. An example of this reaction with iP is shown in Figure 1a. Although the exact chemical mechanism for this reaction is unknown, it is suspected that the enzyme is reduced during the deprotonation of iP to N⁶-(Δ²-isopentenylimino) purine. The purine is then hydrolyzed into adenine and intermediate 3-methyl-2-butenal (Figure 1b).

While the electron acceptor responsible for reoxidizing the reduced enzyme in plant cells is not known, molecular oxygen can do so in vitro.

Alternatively, the reduced enzyme may be reoxidized in vitro by intermediates such as Cu⁺²/imidazole complexes or the artificial electron acceptor dichlorophenolindophenol (DCPIP).

Cytokinin oxidases are known to remove cytokinins from plant cells after cell division, and have also been postulated to be involved in the senescence process. Cytokinin oxidase activities have been shown to positively correlate to the mitosis of endosperm cells in maize kernels, along with the increase in natural cytokinin concentrations. Oxidase activity increases shortly after the increase in endogenous cytokinin levels. A similar correlation was demonstrated with artificially increased cytokinin levels in transgenic

tobacco. Thus, expression of cytokinin oxidases is thought to be involved in the maintenance of hormonal homeostasis in developing plant cells. Because cytokinin oxidases appear to be substrate-inducible, they act in a negative regulatory fashion to reduce elevated cytokinin levels back to basal values. This substrate induction of cytokinin oxidase activity is a significant barrier to potential commercial applications which attempt to manipulate cytokinin levels in transgenic plants through increased cytokinin production.

5

25

30

10 Cytokinin oxidases have been discussed for a number of plant species, including Vinca rosea, beans (Phaseolus vulgaris and lunatus), wheat (Triticum aestivum), tobacco (Nicotiana tabacum), Dianthus caryophyllus, soy (Glycine max), and maize (Zea mays). 15 All of these plant cytokinin oxidases have a similar substrate preference for iP and Z, but show limited or no reactivity with bulky, reduced, or aromatic side chain cytokinins. All also exhibit enhanced activity in the presence of copper plus imidazole. However, these enzymes 20 show substantial variation in both specific activity and molecular weight. This is thought to be linked to the occurrence of glycosylated and unglycosylated variants of the protein, both between and within species.

In the case of the glycosylated cytokinin oxidase, the heavily glycosylated protein may present a carbohydrate-rich surface, preventing antibody formation against peptide epitopes. The glyco-epitopes to which antibodies are raised under these conditions are non-specific, and may prevent isolation of the protein, or clones containing the gene which encodes it, via immuno-chromatography or other immunology-based means. An earlier reported attempt to isolate the gene for maize

15

cytokinin oxidase (ckx1) by immunoscreening of maize cDNA library expression products (Burch, 1992) was unsuccessful.

As demonstrated, the full amino acid sequence and encoding DNA for a cytokinin oxidase has been a long sought after goal in modern plant physiology.

SUMMARY OF THE INVENTION

It is therefore an object of the present invention to provide a means by which recombinant cytokinin oxidase may be produced in quantity so that the effects of cytokinin oxidase on plant growth and metabolism may be studied. It is also an object of the present invention to provide a means for the modification of cytokinin oxidase production in plant cells, in vivo, in order to modulate the endogenous cytokinin level of plant cells to effect altered pathogen resistance and plant growth properties.

The present invention, therefore, is directed to a novel, isolated and substantially purified plant cytokinin oxidizing enzyme, (ckx1), having a molecular weight most preferably of about 60 kD, a sequence length 20 of from about 505 to 565 amino acid residues, preferably 525 to 545 amino acid residues, and most preferably 534 amino acid residues, and having cytokinin inactivating activity. The present invention is also directed to a protein having an amino acid sequence which includes the 25 amino acid sequence of ckx1 (SEQ. ID NO. 1). The invention is directed as well to a protein which has cytokinin inactivating activity and which includes a portion of the amino acid sequence of ckxl at least about 20 amino acid residues in length, where the included 30 portion of the ckxl sequence confers the cytokinin inactivating activity on the protein. The invention is directed to proteins which have cytokinin inactivating activity and have at least about 65% sequence identity to WO 99/06571 PCT/US98/15844

5

ckxl and most preferably at least about 95% sequence identity to ckxl, with the remaining amino acids being conservatively substituted.

The invention is directed, moreover, to substantially isolated nucleic acid polymers encoding 5 ckxl or a cytokinin oxidizing homolog thereof. The nucleic acid polymer most preferably has a nucleic acid sequence of SEQ. ID NO. 3 or the predictable variants thereof described in SEQ. ID NO. 10. The invention is also directed to a substantially isolated nucleic acid 10 polymer which contains a portion of SEQ. ID NO. 2, SEQ. ID NO. 3, or a nucleic acid polymer described by SEQ. ID NO. 10, the portion being at least 60 bp in length. In addition, the invention is directed to nucleic acid polymers which are able to hybridize with SEQ. ID NO. 2, 15 SEQ. ID NO. 3, or a nucleic acid polymer described by SEQ ID NO. 10, under conditions of 0.5% to 2% SSC buffer, 0.1% SDS, and a temperature of 55-65°C. Nucleic acid polymers which encode cytokinin oxidases and meet the above requirements encode proteins of sufficient 20 similarity to ckxl to be generally recognized as equivalents of ckx1 among those skilled in the biochemical arts.

The invention is also directed to a host cell incorporating a vector containing the aforementioned DNA, and to a method for producing ckxl or a homolog thereof using such a host cell. The method preferably comprises first ligating DNA encoding the aforementioned ckxl or a segment or homolog thereof and an appropriate promoter (such as the RB7 root-specific promoter, Conkling, M.A., et al., U.S. Pat. No. 5,459,252; or CaMV35S promotor, Odell, 1985), or a combination of promoters (Hoffman, Patent No. 5,106,739) 3) into an appropriate DNA vector (for instance, pBIN19 for use in Agrobacterium tumefaciens). The vector construct may then be directly

25

30

35

30

35

transformed into a host cell, such as Pichia pastoris (described in Example 2). It may also be incorporated into a secondary vector for transformation into a host cell, such as Agrobacterium tumefaciens, and transformed into a plant cell host (described in Example 4 with Nicotiana tabacum).

Alternatively, for production of larger amounts of the enzyme, the DNA encoding ckx1, or a portion thereof, may be transformed into Pichia, according to the methods described in Example 2, or in Su, et al., 1996 and Skory, et al., 1996. When transformed into Pichia spp., ckx1 is secreted into the culture medium because of the presence of a secretory signal peptide at the N-terminus of the ckx1 coding region. Thus, active enzyme may be readily purified from bulk Pichia cultures without a lysing step. ckx1 produced in such a manner may be used in a biochemical assay to determine unknown concentrations of cytokinin in biological samples, according to the method of Example 3.

A plant host cell generated by the above method may be regenerated into an entire plant. Depending on the promoter used in the vector construct, ckxl may be produced constitutively or by induction through natural or artificial environment factors. Plants transformed with vectors containing tissue-specific or trauma-specific promoters and a sequence encoding ckxl can exhibit altered resistance to certain cytokinin-linked plant pathologies, such as infection by certain nematodal or fungal species.

The discoveries described herein provide an important analytical tool for, and a critical link in, the development of methods by which the manipulation of cytokinin oxidase activity may be used to either inhibit or enhance a variety of cell growth functions in plants in a desired manner. Possible uses include the

development of commercial plants with increased grain production, disease resistance, or with more desirable secondary growth characteristics. The enzyme and its encoding nucleic acids have important uses in the study of plant cell growth cycles and senescence. In addition, many other pharmaceutical and agricultural uses for ckx1 and its gene may be discovered. The enzyme, methods of expressing the enzyme, and methods for its use are described in greater detail below.

Other features and objects of the present invention will be in part apparent to those skilled in the art and in part pointed out hereinafter.

10

20

25

30

35

BRIEF DESCRIPTION OF THE FIGURES, SEQUENCE IDENTIFICATIONS, AND DEFINITIONS

The invention is further disclosed and illustrated by the accompanying figures.

FIG. la & b show an exemplary reaction catalyzed by cytokinin oxidase (Brownlee, 1975), and its putative mechanism as described above, based on Hare, 1994.

FIG. 2 shows agarose gel electrophoresis of RT-PCR DNA fragments which demonstrate that the introns of the ckxl gene have been correctly identified.

FIG. 3 shows the standard spectrophotometric absorbance curve (590 nm) obtained when using ckxl to assay cytokinin concentrations in solution.

FIG. 4 is a diagram of DNA plasmid pJL7.

FIG. 5 is a diagram of DNA plasmid pBI121.

FIG. 6 is a diagram of DNA plasmid pROM8.

FIG. 7 is a diagram of DNA plasmid pROM9.

FIG. 8 is a diagram of DNA plasmid pROM22.

FIG. 9 is a diagram of DNA plasmid pROM24.

FIG. 10 is a diagram of DNA plasmid pROM26.

FIG. 11 is a diagram of DNA plasmid pROM28.

FIG. 12 is a diagram of DNA plasmid pROM29. FIG. 13 is a diagram of DNA plasmid pROM30.

FIG. 14 is a diagram of DNA plasmid pROM32.

ø

FIG. 15 is a diagram of DNA plasmid pROM43.

All Sequence Identification abbreviations of amino acids and nucleotides conform to USPTO and WIPO standards.

SEQ. ID NO. 1 lists the amino acid sequence of naturally occurring ckx1 derived from Zea mays. This sequence was predicted from the genomic DNA derived nucleotide sequence encoding ckx1.

SEQ. ID NO. 2 lists the genomic DNA sequence encoding ckx1, including introns.

SEQ. ID NO. 3 lists the coding DNA sequence for ckx1, with introns excluded. This sequence has been reconstructed in pROM22 of Example 2.

SEQ. ID NO. 4 lists the amino acid sequence of an internal tryptic digest fragment of ckx1.

SEQ. ID NO. 5 lists the amino acid sequence of an internal tryptic digest fragment of ckx1.

SEQ. ID NO. 6 lists the nucleic acid sequence of a degenerate DNA probe used to isolate the genomic DNA encoding ckx1, as described in Example 1. Note that the residues designated "n" in the sequence are the artificial base inosine (I). Normal conventions have been followed for the indication of degeneracies in the sequence.

SEQ. ID NO. 7 lists the nucleic acid sequence of a degenerate DNA probe used to isolate the genomic DNA encoding ckx1, as described in Example 1. Note that the residues designated "n" in the sequence are the artificial base inosine (I). Normal conventions have been followed for the indication of degeneracies in the sequence.

SEQ. ID NO. 8 lists the nucleic acid sequence of a degenerate DNA probe used to isolate the genomic DNA

encoding ckx1, as described in Example 1. Note that the residues designated "n" in the sequence are the

15

20

25

30

artificial base inosine (I). Normal conventions have been followed for the indication of degeneracies in the sequence.

SEQ. ID NO. 9 lists the nucleic acid sequence of a degenerate DNA probe used to isolate the genomic DNA encoding ckx1, as described in Example 1. Note that the residues designated "n" in the sequence are the artificial base inosine (I). Normal conventions have been followed for the indication of degeneracies in the sequence.

SEQ. ID NO. 10 lists the degenerate DNA sequence encoding ckx1. As is well known in the art, the several DNA molecules indicated by this group encode a protein with the amino acid sequence of SEQ. ID NO. 1, also known as ckx1. This group follows the conventional rules of degeneracy in the genetic code. Special modifications necessary for expression in certain organisms which do not follow these conventions could easily be made by an individual of ordinary skill in the art.

SEQ. ID NO. 11 lists the sequence of a synthetic primer used in the PCR removal of introns in example 2.

SEQ. ID NO. 12 lists the sequence of a synthetic primer used in the PCR removal of introns in example 2.

SEQ. ID NO. 13 lists the sequence of a synthetic primer used in the PCR removal of introns in example 2.

SEQ. ID NO. 14 lists the sequence of a synthetic primer used in the PCR removal of introns in example 2.

SEQ. ID NO. 15 lists the sequence of a synthetic primer used in the PCR removal of introns in example 2.

SEQ. ID NO. 16 lists the sequence of a synthetic primer used in the PCR removal of introns in example 2.

SEQ. ID NO. 17 lists the sequence of a synthetic linker construct used in example 2.

SEQ. ID NO. 18 lists the sequence of a synthetic linker construct used in example 2.

15

20

25

30

SEQ. ID NO. 19 lists the sequence of a synthetic primer used in PCR to obtain the tobacco RB7 promoter in example 4.

SEQ. ID NO. 20 lists the sequence of a synthetic primer used in PCR to obtain the tobacco RB7 promoter in example 4.

As used herein, a "substantially purified protein" means that the protein is separated from a majority of host cell proteins normally associated with it or that the protein is synthesized in substantially purified form, such synthesis including expression of the protein in a host cell from a nucleic acid polymer exogenously introduced into the cell by any suitable gene-therapy delivery means.

A "substantially isolated nucleic acid polymer"
means that the mixture which comprises the nucleic acid
polymer of interest is essentially free of a majority of
other nucleic acid polymers normally associated with it.
A "nucleic acid polymer" includes a polymer of
nucleotides or nucleotide derivatives or analogs,
including for example deoxyribonucleotides,
ribonucleotides, etc. Genomic DNA, cDNA and mRNA are
exemplary nucleic acid polymers.

The terms "regulate transcription," "modify transcription," "regulate production," and "modify production," is intended to include promotion and/or repression of transcription or mRNA or production/translation of a protein.

The term "expression regulatory sequence" means a nucleic acid polymer sequence ligated to a protein encoding sequence which, when introduced into a host cell, either induces or prevents expression of that protein. These sequences may or may not also encode

35

proteins used in their regulatory mechanism. Examples of expression regulatory sequences include the CaMV promoter, the ocs terminator, and the tet operator sequences.

The term "gene" is intended to include both endogenous and heterologous genes, and specifically, both genomic DNA which encodes a target protein in a naturally occurring cell, and also cDNA encoding the target protein, for example, wherein the cDNA is a part of a nucleic acid construct such as a plasmid vector or virus which has been introduced into a cell or a cDNA produced by RT-PCR.

The term "vector" is intended to include any physical or biochemical vehicle containing nucleic acid 15 polymers of interest, by which those nucleic acid polymers are transferred into a host cell, thereby transforming that cell with the introduced nucleic acid polymers. Examples of vectors include DNA plasmids, viruses, particle gun pellets, and bacteria such as 20 Agrobacterium tumefaciens. The term "primary vector" is intended to mean the first vector used in a transformation series, either as one step (e.g. a plasmid used to transform a yeast cell), or with a "secondary vector" (e.g. a plasmid used to transform Agrobacterium 25 tumefaciens, which is later used to transform a plant cell).

The term "host cell" is intended to mean the target cell for vector transformation, in which the transferred nucleic acid polymer will be replicated and/or expressed.

The term "conservative substitution," in the context of amino acid sequences, means the substitution of one amino acid in the sequence with another with a side chain of similar size and charge. An example of a conservative substitution would be substituting glutamine for asparagine. Conservative substitutions in a protein =

20

25 .

35

sequence which would be expected to have minimal to no impact on protein structure or function can be readily devised by a person of ordinary skill in the biochemical arts.

The term "plant products" means any cellular material produced by a plant, especially those which may be used for propagation of the plant. Plant products include seeds, rhizomes, leaves, meristem, roots, and buds.

The term "SSC buffer" means a solution of 8.765 g 10 NaCl and 4.41 g sodium citrate in 1 liter of water, pH adjusted to 7.0 by titrimetric addition of 10 N NaOH solution.

The contents of each of the references cited herein are being incorporated by reference in their entirety. 15

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to newly sequenced cytokinin oxidase isolated from the maize plant, Zea mays, designated ckx1, which exhibits a substrate specific cytokinin oxidizing activity. The enzyme has been linked to the development and maturation of kernels in maize, as well as the senescence of plant tissues. The control of these plant functions appears to be achieved by the degradation of endogenous and exogenous cytokinin concentrations. Because ckx1 efficiently oxidizes unsaturated-side-chain free cytokinins and their ribosides, such as iP, Z, and ZR (which also induce production of the enzyme when applied exogenously or endogenously), it is thought that ckx1 rigorously controls the availability of these active cytokinins as a 30 part of plant growth regulation.

During the course of developing the claimed invention, the applicant encountered several difficulties which may explain why the search for a cytokinin oxidase gene has been heretofore unsuccessful. The protein is

10

15

20

25

30

35

expressed at very low levels, and only at certain periods of the plant growth cycle. Therefore, screening a λ -cDNA maize library in E. coli may not yield ckxl simply because the gene was not expressed, or not expressed in detectable amounts, when the library was taken. Also, isolation of the protein may have been a problem for some researchers, since its active form does not survive gel filtration. Only through the development of his own screening process, described in Example 1, was the applicant able to isolate the protein in sufficient purity for tryptic digestion and subsequent sequencing.

Even after the protein was purified, obtaining the

gene sequence for ckxl proved to be difficult. Apparently, the N-terminal end of ckx1 is blocked, so a straightforward Edman degradation determination of its Nterminal sequence was impossible. Only small, internal sequences were determinable after tryptic digestion of the protein, SEQ. ID NO. 4 & 5. Because the location of these fragments in the protein's amino acid sequence was unknown, several problems had to be overcome in order to successfully probe the Zea mays genome for the ckx1 gene, as detailed in Example 1. The small size of the sequenced peptides necessitated using a "bookended" criteria (one probe at either end of the replicated DNA) in order to eliminate non-ckx1 DNA from either side of the ckx1 gene. One could be reasonably certain that the DNA between two probes would be part of the ckx1 gene. A hybridization/ amplification product size criteria of 300 bp was also necessary in order to distinguish between dimerized degenerate primers and PCR products. A simple degenerate strategy was unlikely to work because of the high degeneracy inherent in the particular amino acid sequences available from the tryptic peptides. Initially, when a standard degenerate nucleotide strategy was used, utilizing all possible oligonucleotides encoding the interior amino acid sequences, the low concentration of

15

20

25

30

35

specifically binding primer was not sufficient for the initiation of PCR amplification. The applicant was able to overcome this problem only by using inosine containing degenerate probes with a broader specificity. Also, several of the degenerate probes were too close together to yield products of the target size, or not in the right order in the gene to produce "bookended" products. Only probes SEQ ID NO. 6, 7, 8, & 9 proved to be of use in isolating the ckx1 gene.

The identity of the isolated gene was verified by two independent methods. First, it was verified by testing the affinity of goat antisera to an Escherichia coli produced translation of SEQ. ID NO. 3 for ckxl in maize kernel extracts, as per Example 1. Second, it was confirmed by expressing SEQ. ID No. 3 in Pichia pastoris resulting in the secretion of active cytokinin oxidase as per Example 2.

SEQ. ID NO. 2 lists the complete genomic DNA sequence of ckx1, which yields the glycosylated form of the protein when expressed in Zea mays. The predicted location of the introns in the genomic sequence was verified using the reverse transcriptase- polymerase chain reaction to find the actual transcribed length of RNA, as per Example 1. SEQ. ID NO. 3 lists the coding DNA sequence for ckx1, which yields the amino acid sequence set forth in SEQ. ID NO. 1.

The state of the art of molecular biology is now sufficiently advanced that minor alterations can be made to a DNA sequence with relative ease and precision. A moderately skilled laboratory technician can follow the directions of one of the commercially available site-directed mutagenesis kits (for instance, the GeneEditor™ offered by Promega Corp., Madison, Wisconsin) to effect any number of changes to a DNA nucleotide sequence. Also well known are the general rules governing the genetic code, by which triplet nucleotide codons are translated

into an amino acid sequence by standard biochemical processes. Thus, the applicant considers the group of DNA sequences denoted by the consensus sequence of SEQ. ID NO. 10, which code for the amino acid sequence of ckx1 in SEQ. ID. NO. 1, to be within the present invention. Although some variation in the genetic code and the GC% content occurs amongst some phyla, the rules governing these variations have also been well documented, and are within the reasonable skill of one versed in the molecular genetic arts. Thus, the applicant also considers any other nucleic acid sequence which encodes the amino acid sequence SEQ. ID NO. 1 to be within the scope of the present invention.

In addition, although the understanding of the field 15 of protein biochemistry is not as complete as that of molecular genetics, the person or ordinary skill in the art of biochemistry is capable of predicting, with reasonable certainty, when certain substitutions to the primary amino acid sequence structure of a protein will 20 not result in any appreciable modification of a protein's structure or function. Such conservative substitutions are made by replacing an amino acid in the sequence with another containing a side chain with like charge, size, and other characteristics. For instance, the amino acid 25 alanine, which has a small nonpolar methyl side chain, generally can be replaced by glycine, an amino acid which has a small nonpolar hydrogen side chain, without any noticeable effects. Likewise, the amino acid asparagine, with a moderately bulky, polar ethamide side chain, 30 usually can be replaced with glutamine, which has a moderately bulky, polar propamide side chain, without noticeable effects. To the extent that such conservative substitutions can be made while retaining 65%, preferably 80% or more identity to SEQ. ID NO. 1 and cytokinin 35 oxidizing activity, such altered proteins are within the scope of the present invention.

30

35

Cytokinin oxidases are known to exist in a variety of non-glycosylated and glycosylated forms in several species of higher plants, including maize. This modification is thought to be involved in compartmentalizing cytokinin oxidases for various uses 5 inside and outside the cell. The extent of glycosylation of the enzyme may also account for the wide variety of molecular weights observed between the cytokinin oxidases of various species. However, because substrate specificity, a requirement of molecular oxygen for 10 activity, and copper concentration reaction rate effects in vitro are highly conserved among all higher plant cytokinin oxidases, a common domain and active site structure is believed responsible for the cytokinin oxidizing activity of all enzymes. Thus, the present 15 invention is also directed to a protein which exhibits cytokinin oxidizing activity and which contains an amino acid sequence at least about 20 amino acids in length which is 90% identical (or would be identical with conservative amino acid substitutions) to a similarly 20 sized portion of SEQ. ID NO. 1.

Another object of the current invention is the regulated production of ckx1 in various host cells, either for later bulk isolation, or regulated intracellular production. For instance, ckx1 may be produced in unglycosylated form in prokaryotes, such as E. coli, as illustrated in example 1. More preferably, the protein may be produced in eukaryotes, as illustrated by the Pichia production of example 2. An added benefit of producing the protein in Pichia is that the protein is secreted into the culture media where it may be readily purified. Alternatively, the protein may be produced in higher eukaryotes, more preferably plants, such as the Nicotiana constructs of example 4 either as the glycosylated or non-glycosylated forms. Other examples of suitable host plant cells include Zea mays,

20

25

30

Arabidopsis thaliana, Brassica spp, and Oryza sativa. As illustrated, ckx1 can be produced in plants either in an unregulated fashion, as shown here under the CaMV promoter, regulated by an artificial stimuli, as shown here under a tet operator combined with a CaMV promoter, and regulated by an environmental stimuli, as shown here under the RB7 promotor, which induces root-specific production of a protein in response to nematodal attack.

The several aspects of the present invention,

including the ckx1 protein and the nucleic acid polymers
which encode it, the cytokinin oxidizing activity of
enzymes such as the ckx1 enzyme, and the regulation of
cytokinin levels in plant cells by ckx1, collectively
enable several practical applications, including both
agricultural and research uses.

The applicant has devised an application for bulk cytokinin oxidase which greatly facilitates plant physiology research. Cytokinin oxidase can be reoxidized after oxidizing cytokinins by the synthetic oxidizing agent dichlorophenolindophenol (DCPIP). DCPIP demonstrates a reduced absorbance at 590 nm upon reduction, which can be spectrophotometrically quantified. The cytokinin concentration in a sample may be determined indirectly by measuring the decrease in oxidized DCPIP as ckx1 oxidizes the cytokinins present in the sample. More sensitive redox dyes are also available to increase the sensitivity of the assay. Therefore, it is another object of the present invention to provide a simple, fast, and effective means to assay cytokinin concentrations in a sample.

The applicant has also devised an application for the modified production of ckx1 in plants. Cytokinins are associated with several types of plant pathogenesis, including the formation of nematode feeder cells, and

WO 99/06571 PCT/US98/15844

19

fungal invasion of plant tissues. Thus, the pathogen-exposure-regulated production of ckx1 can modify the efficacy of pathogenesis through cytokinin-utilizing mechanisms such as that utilized by the root-knot nematode, Meloidogyne spp. (Bird, et al., 1980), or fungal species such as Ustilago maydis. Thus, it is an object of the present invention to provide a method of moderating cytokinin-mediated pathogenesis by transforming a plant with a ckx1 producing DNA construct.

The following examples illustrate the principles and advantages of the invention.

5

EXAMPLES

Example 1: Isolation of ckx1 and characterization of its encoding sequence

15 Maize kernels were chosen as the raw material for purification because of the relatively high concentrations of cytokinin oxidase present about a week after pollination. Using the procedure set forth below, approximately 1.66 μ g protein per kg maize yield may be obtained. Field grown maize (Pioneer 3180 or 3379) was hand pollinated, and immature ears were harvested between 5 and 8 days later (Dietrich, 1995). Kernels were harvested immediately, and frozen at -80°C until extraction. After being powdered in liquid nitrogen, the 25 kernels were blended in 1 kg lots with 1700 ml of Buffer A(50 mM Tris, 5 mM EDTA, ascorbic acid 0.4% w/v; 10 mM β mercaptoethanol, pH 8.5). Acid washed PVPP (200 g wet weight, equilibrated w/ Buffer A) was stirred in immediately. The slurry was filtered through Miracloth 30 and centrifuged at 23,500 x g for 15 minutes to remove debris. Polyethyleneimine solution (5% v/v, pH 8.5) was added dropwise to the centrifuged supernatant, to a final concentration of 0.05%. After recentrifugation at 23,500

10

15

20

minutes.

x g for 10 minutes, the supernatant was filtered through a 600 g pad of PVPP (prepared as above). Ammonium sulfate fractionation was performed, and the protein precipitating between 40% and 65% saturation was collected by centrifugation and dissolved in a minimum volume of Buffer B (10 mM Tris, 1 mM EDTA, 1 mM β -mercaptoethanol, pH 8.5). Insoluble material was removed by centrifugation at 35,000 x g for 20 minutes. At this point, glycerol may be added to the supernatant to 10% v/v, allowing the protein to be stored at -80°C indefinitely without loss of activity.

After dialyzing the supernatant from the ammonium sulfate fractionation against Buffer B, the fraction was applied to a DEAE-cellulose column (Whatman DE-52, 500 ml, available from the Whatman Group, Clifton, New Jersey) at the rate of 10 ml/minute. After washing w/buffer B, the column was eluted with a linearly increasing concentration of KCl in Buffer B, to 200 mM over 600 ml. Protein content was measured using the Bradford dye binding assay (Bradford, 1976). Fractions were analyzed for oxidase activity as described below.

Two assays were used to screen purification steps for cytokinin oxidase activity. The first was the Schiff base formation assay measuring the production of 25 dimethylallylaldehyde from iP, as described by Liberos-Minotta (1995), which was used up through the DEAE column step. A second assay, developed by the applicant, was used in the remaining purification steps. In this assay, the transfer of reducing equivalents from 30 isopentenyladenine to dichlorophenolindophenol (DCPIP), catalyzed by ckx1, allows the observance of reactivity by measuring absorbance change at 590 nm. In a final volume of 250 μ l, the assay contains: 100 mM Phosphate buffer, pH 7.0; 1.0 mM EDTA; 0.05 mM DCPIP; 0.1 mM iP; 100 μ g/ml 35 BSA; and the sample tested. After the addition of the enzyme, absorbance change is read at 590 nm for 10

35

After purification on the DEAE column, the major pooled active material was dialyzed against Buffer C (20 mM Tris, 0.5 M NaCl, 1.0 mM CaCl2, pH 7.4), and applied to a concanavalin A agarose column (100 ml, from Sigma Aldrich, St. Louis, Missouri) and washed w/ Buffer C (270 ml). Glycosylated proteins were eluted with a step gradient of buffer C containing $\alpha\text{-}D\text{-methylmannoside}$ to 1 M over 400 ml. The relatively long retention time when eluted under these conditions indicates that the glycosylated form of ckxl was isolated. Active fractions 10 from the lectin-affinity chromatography were then dialyzed against Buffer D (10 mM Tris, 1 mM EDTA, pH 8.5) and applied to a high resolution anion exchange column (FPLC MonoQ, 1 ml, from Amersham Pharmacia Biotech, Ltd., San Francisco, California), and eluted with a linear 15 gradient of KCl to 0.12 M over 24 minutes at 1 ml/minute. The active fractions from the ion exchange column were then concentrated, dialyzed against Buffer B, brought to 1.5 M ammonium sulphate and applied to a hydrophobic interaction column (FPLC phenylsuperose, 1 ml, Pharmacia) 20 equilibrated in Buffer B containing 0.6 ammonium sulfate. After washing with 0.6 M ammonium sulfate for 25 minutes, the concentration of ammonium sulfate was reduced successively to 0.45 M over 15 minutes and then to zero over 60 minutes. 25

Native gel electrophoresis was performed as illustrated in Ornstein (1964) and Davis (1964). Gels were then stained for cytokinin oxidase activity by the DCPIP procedure described above. Enzyme activity was revealed as a transparent band against a blue background. Denaturing SDS polyacrylamide gel electrophoresis was then carried out as illustrated in Laemmli (1970). When testing fractions for homogeneity, the gel was stained as described by Møller (1995). At the final purification step, the enzyme was stained with Coomassie Blue R250. The purified protein was analyzed by tryptic digestion, HPLC separation of digest, and Edman degradation

sequencing of the tryptic polypeptides. Several polypeptide sequences were obtained from this analysis, including SEQ. ID NOS. 4 and 5. From these sequences, reverse translation primer probes, SEQ. ID NOS. 6,7,8, and 9, were devised, with inosine substituted at highly degenerative positions. Primers SEQ. ID NOS. 6 and 9 were then combined with maize genomic DNA, and hot-start touchdown PCR was performed (Ault, 1994) for 40 cycles. PCR products were separated on agarose gel, and an 10 approximately 440 bp fragment was chosen to use as a hybridization probe. The identity of the fragment was confirmed by showing that it could be amplified by PCR with the nested internal primers SEQ. ID NOS. 7 and 8. The fragment amplified by the primers SEQ. ID NOS. 6 and 15 9 was then ligated into linearized pCRII DNA and transformed into E. coli (INVαF', Invitrogen Corp., Carlsbad, California). After cloning and reisolation of DNA, plasmid inserts were sequenced using the Prism dideoxy terminator method of Applied Biosystems, Foster 20 City, CA, to verify that the sequenced tryptic digest polypeptides were encoded by the fragment.

Once the large fragment had been verified, it was labeled with 32P by primer extension using the Klenow fragment of DNA polymerase and primers SEQ. ID NOS. 6 and 25 9. Maize genomic library phage (in λ -FIXII, from Stratagene, La Jolla, California) were diluted in SM Buffer, and appropriate numbers added to freshly prepared E. coli (XL1-Blue MRA (P2), Stratagene) in 10 mM MgSO4 and incubated at 37°C for 15 minutes. NZY top agar at 48°C was 30 added and the mixture plated onto NZY agar plates. After incubation for approximately 8 hours at 37°C, plates were cooled to 4°C for 2 hours and phage were adsorbed onto sheets of Hybond N membrane (Amersham Pharmacia Biotech, San Francisco, California). Membranes were air-dried for 10 minutes, and incubated successively with 0.5 M NaOH 35 plus 1.5 M NaCl, 500 ml, 5 minutes; 0.5 Tris-Cl pH 8.0 plus 1.5 M NaCl, 500 ml, 5 minutes; and 2 x SSC, 500 ml,

15

20

25

30

5 minutes. They were blotted dry and baked at 80°C until dry (approximately 15 minutes). Membranes were prehybridized at 45°C for less than one hour in 50% formamide, 5 x SSPE, 2 x Denhardt's solution, 0.2% SDS, $100-200~\mu g/ml$ denatured herring sperm or calf thymus DNA (Maniatis, 1990).

The labeled DNA fragment was then denatured at 100°C for 5 minutes, added to the pre-hybridization solution, and hybridized for 16 hours at 45°C. For the primary screen, phage were plated at a density of 500 pfu/cm2 and membranes were washed at high stringency. For subsequent plaque purification, candidate phage were plated at a density of 70 pfu/cm² and 2 pfu/cm² and membranes were washed at medium stringency. After three rounds of purification, subfragments of the insert were removed from positive phage DNA by restriction and subcloned into pBluescript (Stratagene) for characterization by restriction digestion and sequence analysis. Two overlapping plasmid subclones, pROM2 (a HindIII insert) and pROM3 (an Xho-BamHI insert) each contained part of the gene for ckx1. These overlapping sections have been fused into the plasmid clone pROM10. The plasmids pROM2, pROM3, and pROM10 have been deposited with the American Type Culture Collection as ATCC Nos. 209573, 209572, and 209571, respectively. The sequence of the cloned DNA in pROM2 and pROM3 provided the genomic sequence of ckx1, SEQ. ID NO. 2, which was verified by the inclusion of sequences coding for the tryptic digest fragments obtained above.

The location of the introns in the ckx1 gene, and the coding sequence for ckx1 (SEQ. ID NO. 3) was verified by use of the reverse transcriptase polymerase chain reaction (RT-PCR) according to the following procedure.

Total RNA(2-4 μ g, DNAase I-treated) from kernels harvested five days after pollination (5 DAP) was primed for RT-PCR using oligonucleotides bracketing the intron

sites. Primers 2031f (ckx1 genomic sequence 2031-2050) and XBH1 (reverse complement of ckx1 genomic sequence 2553-2570) covered the first intron site. Primers 3160f (ckx1 genomic sequence 3160-3179) and 3484r (reverse 5 complement of ckx1 genomic sequence 3465-3484) covered the second intron site. Reverse transcription was at 50°C for 50 min. with 2000 Superscript II (Gibco-BRL) in 20 μ L total volume with 25 mM Tris-Cl, pH 8.3, 37.5 mM KCl, 1.5 mM MgCl₂, 0.5 mM dNTPs, 5mM dithiothreitol, 40U RNAasin 10 (Promega, Madison, Wisconsin). PCR was performed with 4-10% of the RT reaction product as template and 1U Taq polymerase in 1X PCR buffer (Roche Diagnostics, Basel, Switzerland), 200 μM dNTPs, and 0.5 μM each primer. Reaction conditions were: an initial denaturation at 95° C 15 for four minutes followed by thirty-five cycles of 95° denaturation for one minute, 60° annealing for one minute, and 72° extension for one minute. A final four minute extension was carried out at 72°. PCR products were resolved on 1.5% agarose gels. PCR products were excised 20 from gels and sequenced to determine splice site junctions.

RT-PCR of maize kernel RNA (5 days after pollination) with primers designed to span the first and second intron locations demonstrated PCR product sizes consistent with splicing out of these introns in the mature oxidase mRNA. The primers bracketing the first intron should give a 539 bp product if the intron is present and a 127 bp product if it has been spliced out. Likewise, the primers bracketing the second intron should give a 324 bp product if the second intron is present and a 232 bp product if it has been spliced out. As shown in

10

15

20

25

30

Figure 2, the PCR products were 127 bp and 232 bp respectively, indicating that the introns had indeed been spliced out. Sequence analysis of the fragments confirmed that splicing had occurred as predicted.

The identity of the ckxl protein and gene were further verified by the following immunological technique.

Polyclonal antibodies were raised in goats to the peptide produced by expression of a ckxl gene fragment in E. coli. This avoided the presentation of a glycosylated surface when raising antibodies to the gene product and the problems encountered by Burch, et al., when raising antibodies to naturally occurring ckx1. Goat antibodies from immunized and unimmunized animals were partially purified by sodium sulfate precipitation (Willams, et al., 1967). Affinity columns were prepared by coupling these purified antibodies (2 mg) to Aminolink Plus gels (1 mL, Pierce) at pH 10, following the manufacturer's protocol. Activity depletion assays were performed by adding 0.2 mL (27 μ g) of a maize ConA-fractioned oxidase preparation plus 0.8 mL phosphate buffered saline (PBS) to each column. The columns were capped and incubated for one hour at room temperature. Eluate was collected and assayed for cytokinin oxidase activity.

Antibodies to ckx1 recognize the major maize cytokinin oxidase enzyme. A column containing immobilized anti-ckx1-fragment antibody was able to deplete cytokinin oxidase activity from a ConA-fractionated maize extract. A control column of unimmunized goat antibodies was not able to do so.

Example 2: Expression of ckx1 in Pichia pastoris

ckx1 protein may be produced in bulk by the following procedure for use in applications such as the cytokinin assay of Example 3, or application to plant materials.

Expression of ckxl in Pichia pastoris was carried out in four stages:

- Step 1. Removal of the introns from ckxl
- Step 2. Removal of the maize promoter and construction of the appropriate expression cassette using the intron-less construct
 - Step 3. Transformation of the final construct into Pichia and
 - Step 4. Expression of ckxl in Pichia

Removal of the right-most intron was accomplished by splicing by overlap extension (Horton et al., 1989) and for the left-most intron by ligation of suitable restriction fragments. The resulting intronless cassette was inserted into the Pichia expression vector pPICZ-A to give the expression construct pROM24 (FIG. 9). This construct was introduced into the requisite Pichia host and grown in the presence of methanol to induce ckx1 expression. Appropriate control Pichia lines (containing the vector alone or a recombinant expressing human serum albumin) were grown in parallel.

No cytokinin oxidase activity was observed in Pichia cell lysates containing ckx1 or the controls at any time during the growth curve. However, the Pichia line harboring ckx1 expressed and secreted high levels of cytokinin oxidase activity into the growth medium. No activity was observed in control supernatants. This provided further verification that ckx1 does indeed encode a cytokinin oxidase.

•

Step 1. Intron removal: The second intron (SEQ. ID NO. 2 residues 3219-3312) was removed by splicing by overlap extension with selected ckxl restriction fragments as templates to limit artifactual priming. The following table lists the primers and templates used.

Intron	Left Primer	Right primer	Template DNA
amplification #1	TGGGAATTCCATGGGGAGA TGGTGACGTGCTC (SEQ. ID NO. 11)	GCCGTCCCACATGGATTTGT TGAGGGGGTAGAC (SEQ. ID NO. 12)	pROM2 Nco1/PinA1 (700 bp) fragment
amplification #2	CTCAACAAATCCATGTGGG ACGACGGCATGTCGGCGG (SEQ. ID NO. 13)	GCGGTCTAGATCTAAA ACATGCATGGGCTATCATC (SEQ. ID NO. 14)	pROM2 390 bp PinA1 + Vspl
amplification #3	ATGGGAATTCCATGGGGAG ATGGTGACGTGCTC (SEQ. ID NO. 15)	GCGGTCTAGATCTAAA ACATGCATGGGCTATCATC (SEQ. ID NO. 16)	Products from amplifications #1 and # 2

PCR products from reactions #1 and #2 were gel-purified 10 and used in the final PCR step. The final product from reaction #3 was cloned and sequenced and a PflM1/ Xbal subfragment was substituted for the intron-containing PflM1/ Xbal subfragment of pROM7. The construct was designated pROM19. The first intron (SEQ. ID NO. 2 15 residues 2113-2524) was then removed from pROM19 by replacement of the DNA between the restriction sites PinAl and Ncol with a linker constructed from the oligonucleotides CCGGTTTTGGTACCGGT (SEQ. ID NO. 17) and CATGACCGGTACCAAAA (SEQ. ID NO. 18). The product was 20 designated pROM20. Extraneous linker-associated bases were removed by digestion with PinAl followed by religation. The product, designated pROM22 (FIG. 8), contained the three fused ckx1 exons and the maize ckx1 promoter. 25

Step 2. The Pichia expression cassette: The maize promoter was removed by partial digestion of pROM22 (FIG. 8) with AatII, filling in the sticky ends with T4 DNA polymerase, and redigestion with BglII. The exon fusion

(containing ckxl and including its putative signal peptide) was ligated into the Pml1/BsmBl restriction sites of pPICZ-A (Easy-Select Pichia Expression Kit version B, Invitrogen Corp.). The resulting plasmid was designated pROM24 (FIG. 9).

- Step 3. Transformation into Pichia strain X33 as described in the Invitrogen protocol: The plasmid pROM24 (FIG. 9) (10 μg) was digested with Dral and electroporated into competent X33 cells in a 2 mM cuvette at 1.75 kV (GenePulser, Bio-Rad Laboratories, Hercules, California). Selection on YPDs with 100 μg/mL zeocin resulted in many colonies. One (PPckx1) was selected for expression studies.
- 15 Step 4. Expression of the oxidase: The transformant PPckx1 was inoculated into BMGY medium (50 mL) and grown overnight. Cells were pelleted, resuspended in BMMY (containing 0.5% v/v methanol), diluted to an A₅₀₀=1 and grown at 30°C with vigorous shaking. Additional methanol was added to 0.5% v/v at 24, 48 and 72 hours postinoculation. Samples were harvested for assay of cytokinin oxidase activity in cell lysates or in culture supernatants. Pichia strains X33 (WT, no insert) and GS115, (secreted human serum albumin insert) served as controls.

Example 3: Use of Recombinant Cytokinin Oxidase in a Rapid Assay Method for Cytokinin

Cytokinins were measured by mixing 100 μ L of a buffer mixture containing phosphate buffer (250 mM, pH 7.0), EDTA (2.5 mM) and DCPIP (0.125 mM), and an excess of recombinant cytokinin oxidase with solutions (150 μ L) of zeatin at various concentrations. The net change in absorbance was measured at 590 nm.

25

30

Figure 3 illustrates the change in absorbance when the assay is used to measure the cytokinin zeatin. The method is capable of measuring as little as 2 nmol zeatin but, the major advantage of the assay over the prior art is its rapidity. Assays can be preformed in as little as five minutes, significantly faster than radioimmunoassays (MacDonald and Morris, 1985).

Further, the method can be integrated into cytokinin production systems by coupling the ckx1 gene to such cytokinin producing genes as ipt or tzs, in order to assay cytokinin production in vitro.

Example 4: Unregulated and Regulated Expression of ckxl Constitutively and in the Roots of Nicotiana tabacum

The following procedure, which produces tobacco plants altered to express ckxl constitutively and in their roots, is a slight modification of the standard protocols described in Draper, et al., 1988.

Nicotiana tabacum cultivar Xanthi is a standard tobacco line. Disarmed Agrobacterium tumefaciens strains such as LBA4404 (Hoekema, et al., 1985) are used. Murashige and Skoog salts, phytagar, sucrose, etc. are reagent or tissue-culture grade.

Three separate constructs were made with the ckxl coding sequence (SEQ. ID NO. 3) to effect three different patterns of ckxl expression in transformed tobacco plants. Constructs were based on the BIN19 plasmid primary vector (which includes an Agrobacterium compatible replication origin and kanamycin selection markers, Bevan, et al., 1984). The following constructs were made:

CaMV-ckxl-nos: The cauliflower mosaic virus promoter with a nos enhancer (U.S. Patent No. 5,530,196), are present in pBI121 (FIG. 5) (available from Clonetech, Palo

Alto, California). The 6-glucuronidase gene of pBI121 was excised with a BamHI/EcoIcrI digest. The coding sequence of ckx1 (SEQ. ID NO. 3) was obtained by a BglII digest of pROM26 (FIG. 10) (pROM24 (FIG. 9) altered by site-directed mutagenesis to contain another BglII and an XhoI restriction site). The final construct pROM30 (FIG. 13), which induces strong constitutive expression of ckx1, was created by digesting the altered pBI121 with BamHI and ligating in the ckx1 coding sequence.

10 CaMV-tet-ckx1-ocs: The ckx1 coding region of pROM26 (FIG. 10) was isolated by BglII digestion and ligated into the BamHI site of pUCA7-TX (Gätz, et al., 1992) to form pROM32 (FIG. 14). The tetracycline-regulated operator element (U.S. Patent No. 5,464,758) from pUCA7-15 TX and the inserted coding region were excised from pROM32 (FIG. 14) by PvuII digestion. The final construct pROM29 (FIG. 12), was produced by ligating the excerpt into the Sall site of pJL7 (FIG. 4) (a BIN19 type plasmid). When this construct is introduced into tobacco 20 previously transformed to express the tet repressor protein, no ckx1 activity will be expressed until repression is relieved by addition of tetracycline. This construct may be of particular use in host organisms where strong constitutive expression of ckxl results in 25 abnormal growth patterns.

RB7-ckx1-nos: The tobacco RB7 root specific promotor (U.S. Patent No. 5,750,386), was obtained by the following method. A fragment containing the promoter was PCR-amplified from tobacco genomic DNA using

GACACCATTCCAAGCATACCCC (SEQ. ID NO. 19) and GTTCTCACTAGAAAAATGCCCC (SEQ. ID NO. 20) as primers. This 1400 bp product was ligated into the pCRII plasmid =

25

30

(Invitrogen) to produce pROM8 (FIG. 6). The HindIII-EcoRI region of the insert, containing the nematode-specific portion of the promoter, was then excised and ligated into the HindIII-EcoRI site of pBluescriptII KS+ (Stratagene) to produce pROM9 (FIG. 7). The EcoRI-NsiI fragment of pROM24 (FIG. 9), containing the ckxl coding sequence, was excised and ligated into the EcoRI-PstI site of pROM9, to make pROM28 (FIG. 11). The final construct pROM43 (FIG. 15), which induces expression of ckxl in roots when the transformed plants' roots are attacked by nematodes, was produced by ligating a HindIII-SacI fragment of pROM28 into the HindIII-SacI site of pBI121 (FIG. 5).

·•.	Media Component	MSS	PC	sī_	MSSK
15	MS Salts (g/l)	4.3	4.3	4.3	4.3
13	Sucrose (g/l)	30.0	30.0	30.0	30.0
	Phytagar (g/l)	7.5	5.0	5.0	7.5
	NAA (mg/1)	0	1.0	1.0	Ó
20	BAP (mg/l)	0	0.1	0.1	0
	Timetin (mg/l)	0	0	200	200
	Kanamycin (mg/l)	0	. 0	50.0	50.0
	рН	5.7	5.7	5.7	5.7

Nicotiana was continuously maintained by axenic shoot tip culture on MSS and sub-cultured at 4 week intervals.

The three binary plasmid constructs described above were electroporated into the disarmed A. tumefaciens host and transformants were grown under suitable selection (An, et al. 1985). Late-log phase cultures were used for transformation.

Young axenic tobacco leaves (3 to 4 weeks after tip culture) were dissected into 4 to 6 segments, excluding

15

the largest vasculature. Segments were cultured on PC, abaxial side up, for 48 hours. The leaf pieces were then soaked in transformed A. tumefaciens culture diluted with water (1:1), for 1 hour. Pieces were then placed on the original PC medium for 48 hours. The leaves were then washed with water thoroughly and placed on SI medium and removed to fresh SI medium every 7 to 10 days. Although no adverse developmental effects were observed with Nicotiana transformants, the use of a non-substrate cytokinin such as benzylaminopurine, or tetracycline repression, may be needed for the culture of some host plants. Shoots were removed onto MSSK media when 1 cm long. Successive tip culture was carried out for 2 to 3 transfers, after which the transgenic plants were maintained on MSS media

In light of the detailed description of the invention and the examples presented above, it can be appreciated that the several objects of the invention are achieved. The explanations and illustrations presented herein are intended to acquaint others skilled in the art with the invention, its principles, and its practical application. Those skilled in the art may adapt and apply the invention in its numerous forms, as may be best suited to the requirements of a particular use.

25 Accordingly, the specific embodiments of the present invention as set forth are not intended as being

exhaustive or limiting of the invention.

10

BIBLIOGRAPHY

An, G., et al., 1985: "New cloning vehicles for transformation of higher plants," EMBO J. 4:277-84

Ault, G., 1994: "Type-specific amplification of viral DNA using touchdown and hot start PCR," J. Virol.

Meth. 46:145-56.

Bechtold, N., et al., 1993: "In planta Agrobacterium mediated gene transfer by infiltration of adult Arabidopsis thaliana plants," CR Acad. Sci. Paris Sciences del la vie/ life sciences 316:1194-99.

Bevan, M., 1984: "Binary Agrobacterium vectors for plant transformation," Nuc. Acids Rsrch. 12:8711-21.

Bird, A.F., et al., 1980: "The involvement of cytokinins in a host-parasite relationship between the tomato(Lycopersicon esculentum) and a nematode (Meloidogyne javanica), "Parasitology 80:497-505.

Bradford, M., 1976: "A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding,"

20 Analytical Biochem. 72:248-54.

Brownlee, B.G., et al., 1975: "3-Methyl-2-butenal: An Enzymatic Degradation Product of the Cytokinin, N^6 -(Δ^2 -isopentenyl)adenine," Can. J. Biochem. 53:37-41.

Burch, L.R., et al., 1992: "Cytokinin Oxidase and the Degradative Metabolism of Cytokinins," in Kaminek, et al. Physiology and Biochemistry of Cytokinins in Plants. pp. 229-32, STP Academic Publishing, The Hague, Netherlands.

Chen, H., et al., 1996: "Novel methods of generating specific oligonucleotide inhibitors of viral polymerases." Methods in Enzymology 275:503-20.

Davis, B., 1964: "Disk Electrophoresis II. Method and application to human serum proteins," <u>Ann. N.Y. Acad.</u> Sci. 121:404.

20

30

Dietrich, J.T., et al., 1995: "Changes in cytokinins and cytokinin oxidase activity in developing maize kernels and the effects of exogenous cytokinin on kernel development," Plant Physiol. Biochem. 33:327-36.

Draper, J., et al., 1988: <u>Plant Genetic</u>

<u>Transformation and Expression: A Laboratory Manual</u>.

Blackwell Scientific Publications.

Gätz, C., et al., 1992: "Stringent repression and homogenous de-repression by tetracycline of a modified CaMV 35 S promoter in intact tobaccod plants." Plant J. 2(3):397-404.

Hare, P.D., et al., 1994: "Cytokinin oxidase: Biochemical features and physiological significance," Physiologia Plantarum 91:128-35.

Hoekema, A., et al., 1985: "Non-oncogenic plant vectors for use in Agrobacterium binary systems," <u>Plant</u>.

Mol. Biol. 5:85-89.

Horton, R.M., et al., 1989: "Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension," Gene 77:61-8.

Koziel, et al., 1993: "Field performance of elite transgenic maize plants expressing an insecticidal protein form *Bacillus thuringiensis*," <u>Bio/Technology</u> 11:194

Laemmli, U.K., 1970: "Cleavage of structural proteins during the assembly of the head of bacteriophage T4," Nature 227:680-685.

Liberos-Minotta, C., et al., 1995: "A colorimetric Assay for Cytokinin Oxidase," <u>Analytical Biochem.</u> 231:339-341.

MacDonald, E.M.S., et al., 1985: "Isolation of cytokinins by immunoaffinity chromatography and isolation by HPLC-radioimmunoassay," Methods in Enzymology 110: 347.

Maniatis, T., et al., 1990: Molecular Cloning. A

Laboratory Manual 2nd Ed. Cold Spring Harbor Laboratory

Press.

30

Møller, H.J., et al., 1995: "Improved method for Silver Staining of Glycoproteins in Thin Sodium Dodecyl Sulfate Polyacrylamide Gels," <u>Analytical Biochem.</u> 226:371-74.

Odell, et al., 1985: "Identification of DNA sequences required for activity of the cauliflower mosaic virus 35S promoter," Nature 313:810.

Ooms, G., et al., 1987: "Genetic transformation in two potato cultivars with T-DNA from disarmed

10 Agrobacterium, " Theor. Appl. Genet. 73:744-50.

Ornstein, L., 1964: "Disk Electrophoresis I. Background and theory," Ann. N.Y. Acad. Sci. 121:321.

Potrykus, 1991: "Gene transfer to plants: assessment of published approaches and results," Annu. Rev. Plant Physiol., Plant Mol. Biol., 42:205.

Singer, B.S., et al., 1996: "Libraries for genomic SELEX," Nucleic Acids Resrch. 25:781-86.

Skory, C.D., et al., 1996: "Expression and secretion of the Candida wickerhamii extracellular beta-glucosidase

gene, bgls, in Saccharomyces cerevisiae, "Current Genetics 30:417-422.

Smith, C.T.S., et al., 1988: "Antisense RNA inhibition of polygalacturonase gene expression in transgenic tomatoes," <u>Nature</u> 334:724-26.

Su, W., st al., 1996: "Identification in vitro of a post-translational regulatory site in the hinge 1 region of Arabidopsis nitrate reductase," Plant Cell 8:519-27.

Van der Krol, A.R., et al., 1990: "Inhibition of flower pigmentation by antisense CHS genes: promoter and minimal sequence requirements for the antisense effect," Plant Molec. Biol. 14:457-66.

Williams, C. A, et al., 1967: Methods in Immunology and Immunohistochemistry I p. 319.

5

WE CLAIM AS OUR INVENTION:

- 1. A substantially purified protein which exhibits cytokinin oxidizing activity, selected from the group consisting of:
 - (a) SEQ. ID NO. 1,
- (b) a protein having an amino acid sequence which includes the amino acid sequence of SEQ. ID NO. 1,
 - (c) a protein having an amino acid sequence which includes a portion of the amino acid sequence of SEQ. ID NO. 1, the included portion being at least about 20 amino acid residues in length and conferring the cytokinin oxidizing activity on the protein, and
 - (d) a protein including an amino acid sequence with at least about 65% sequence identity to SEQ. ID NO. 1, the remainder of amino acid residues being conservatively substituted.
 - 2. The protein of claim 1 wherein the protein is purified.
 - 3. The protein of claim 1 which is SEQ. ID NO. 1.
 - 4. The protein of claim 1 produced by a host cell transformed with a vector containing a nucleic acid polymer which encodes the protein of claim 1.
 - 5. A substantially isolated nucleic acid polymer encoding a protein of claim 1.
 - 6. The substantially isolated nucleic acid polymer of claim 5 which encodes SEQ. ID NO. 1.
 - 7. A substantially isolated nucleic acid polymer which encodes a protein which exhibits cytokinin oxidizing activity, wherein the nucleic acid polymer is selected from the group consisting of:
 - (a) SEQ. ID NO. 2,

PCT/US98/15844

5

10

15


- (b) SEQ. ID NO. 3,
- (c) a nucleic acid polymer with a sequence described by SEQ. ID NO. 10,
- (d) a nucleic acid polymer whose sequence contains a sequence selected from the group consisting of SEQ. ID NO. 2, SEQ. ID NO. 3, or a nucleic acid polymer with a sequence described by SEQ. ID NO. 10.
- (e) a nucleic acid polymer which contains at least one 60 base pair portion, which encodes an amino acid sequence which confers cytokinin oxidizing activity upon the encoded protein, of a nucleotide sequence selected from the group consisting of SEQ. ID NO. 2, SEQ. ID NO. 3, and a nucleic acid polymer with a sequence described by SEQ. ID NO. 10,
- (f) a nucleic acid polymer which encodes a protein including an amino acid sequence with at least about 65% sequence identity to SEQ. ID NO. 1, the remainder of amino acid residues being conservatively substituted,
 - (g) a nucleic acid polymer which hybridizes to a nucleotide sequence selected from the group consisting of SEQ. ID NO. 2, SEQ. ID NO. 3, and a nucleic acid polymer with a sequence described by SEQ. ID NO. 10, under a wash stringency equivalent to 0.5% to 2% SSC buffer, 0.1% SDS, at 55-65°C, and
- (h) a nucleic acid polymer having a nucleotide sequence complementary to any of the nucleic acid sequences (a) (g).
 - 8. The substantially isolated nucleic acid polymer of claim 7 wherein the polymer contains a sequence described by SEQ. ID NO. 10 or a sequence complementary to a sequence described by SEQ. ID NO. 10.
 - 9. The substantially isolated nucleic acid polymer of claim 7 wherein the polymer is SEQ. ID No. 2 or its complementary sequence.

- 10. The substantially isolated nucleic acid polymer of claim 7 wherein the polymer is SEQ. ID No. 3 or its complementary sequence.
- 11. A host cell transformed with a vector containing a deoxyribonucleic acid polymer which encodes the protein of claim 1.
- 12. The host cell of claim 11, wherein the host cell is a plant cell.
- 13. The host cell of claim 12, wherein the host plant cell is selected from the group consisting of:
 - (a) Nicotiana tabacum,
 - (b) Arabidopsis thaliana,
 - (c) Zea mays
 - (d) Brassica spp
 - (e) Oryza sativa
- 14. The host cell of claim 11 wherein the host cell is selected from the group consisting of:
 - (a) Pichia pastoris
 - (b) Escherichia coli
- 15. A plant regenerated from the host plant cell in claim 12.
- 16. A plant product from the regenerated plant of claim 15.
- 17. The plant product of claim 16, wherein said plant product is selected from the group consisting of seeds, leaves, stem cultures, rhizomes, and bulbs.
- 18. A method for producing the protein of claim 1 in a host cell, essentially comprising

- (a) constructing a vector containing DNA encoding the protein of claim 1 and an expression regulatory sequence operational in the host cell;
- (b) transfecting a host cell suitable for protein production with the vector; and
 - (c) expressing the protein in the host cell.
 - 19. The method of claim 18 wherein the vector is selected from the group consisting of:
 - (a) a plasmid comprised of DNA,
 - (b) Agrobacterium tumefaciens
 - 20. The method of claim 18, wherein the host cell is selected from the group consisting of:
 - (a) Pichia pastoris
 - (b) Escherichia coli
 - 21. The method of claim 18 wherein the host cell secretes said protein into a culture medium, and wherein the method further comprises purifying said protein from the culture medium.
 - 22. The method of claim 18 further comprising the step of reconstituting the host cell into an organism.
 - 23. The method of claim 18, wherein the host cell is a plant cell.

- 24. The method of claim 23, wherein the host plant cell is selected from the group consisting of:
 - (a) Nicotiana tabacum,
 - (b) Arabidopsis thaliana,
 - (c) Zea mays
 - (d) Brassica spp
 - (e) Oryza sativa
- 25. A method of moderating cytokinin-associated pathogenesis in a plant comprising transforming a plant cell with a nucleic acid polymer construct which contains:
- (a) a nucleic acid polymer encoding the protein of claim 1, and
- (b) an expression regulatory sequence operational in the host plant; and regenerating a plant from the transformed plant cell.
- 26. A method as set forth in claim 25 wherein the expression regulatory sequence is selected from the group consisting of constitutive promoters, inducible promoters, repressors, and enhancers.
- 27. A method of detecting cytokinin concentrations in a sample essentially comprising:
- (a) adding to a buffered sample known amounts of dichlorophenolindophenol and an excess IU activity producing amount of the protein of claim 1;
- (b) measuring the net change in absorbance of light at 590 nm; and
- (c) comparing this net absorbance to a standard curve generated from known concentrations of cytokinin.

1 / 8



(1-1 sopentenyl) adenine

FIG. 2A


UERIFICATION OF CKXI GENE INTRON


LOCATIONS BY RT-PCR


1 2 3 4 56




FIG. 2B VERIFICATION OF CKX! GENE INTRON LOCATIONS BY RT-PCR 1234567











6 / 8





LISTING SEQUENCE

$\dot{\circ}$
Roy C
Ph.D.,
Morris
<110>

<120> A CYTOKININ OXIDASE

1491 OMO <130>

<140><141>

5

06/054,268 1997-07-30 <150><151>

20 <160> 2.0 PatentIn Ver. <170>

10

<210><211><211><211><212><212><213>

mays 1 534 PRT Zea

Ala Gly Leu Leu Tyr Tyr 5 Val Val)> 1 Ala <400> Met 1

Gly Arg 30 Leu Gly Asp Asp Thr Gly Ala Leu Ala 20 Ala His

Arg	Ile	Asp 80	Tyr	Phe	Ala	Ala	Arg 160	Gly	Gly	Gly
Leu	Asn	Gly	Pro 95	Ala	Ala	Asp	Ala	Val 175	His	His
Lys	Gly	Thr	Trp	Gln 110	Asp	Val	Leu	Thr	Arg 190	Gly
G1y 45	Phe	Ser	Gly	G1y	G1y 125	Tyr	Ser	Leu	Phe	Thr 205
Asp	Asp 60	Ser	Pro	Met	Leu	Arg 140	Ala	Tyr	Ala	Ile
Leu	Thr	Pro 75	Thr	Leu	Ser	Gly	Arg 155	Leu	Gln	Val
Ala	Ser	Tyr	Ser 90	Ser	Ala	Asp	ren	Tyr 170	Gly	Asp
Leu	Ala	Leu	Asn	His 105	Met	Ala	Val	Asp	Ser 185	Met
Ala 40	Ala	Val	Ala	Gly	Asn 120	Ser	Asp	Asn	Ile	Glu 200
Ala	Ala 55	Ala	Ala	Arg	Val	Val 135	Ile	Trp	Gly	Leu
Leu	Thr	Ala 70	Ser	Gly	Val	Asn	Trp 150	Ser	Ala	Val
Ser	Ala	Pro	Leu 85	Arg	Val	Ile	Val	Arg 165	Asn	Asn
Ala	Asn	Leu	Leu	Phe 100	Gly Val	Gly	Gln	Pro	Ser 180	Ser
Pro 35	Ser	Ala	Ala	Ala	G1y 115	Pro	Glu	Ala	Leu	Ile 195
Trp	Asp 50	Ser	Val	Ile	Pro	Pro 130	Gly	Val	Thr	Gln
Pro	Thr	Thr 65	Leu	Thr	Ala	Ala	G1y 145	Gly	б1у	Pro
	•									
•					•					

8	11e 240	Tyr	Pro	G1 u	Thr	Gly 320	Tyr	Ser
A C	Arg	Val 255	Ala	Val	Asn	Ala	Asn 335	Ala
rie e	Ala	Phe	Thr 270	Tyr	Ala	Leu	Leu	Leu 350
ren	Arg	Arg	Leu	Ser 285	Leu	Ala	Thr	G lu
Asp 220	Thr	Val	Arg	Met	Asp 300	Val	Ala	Gln
Ala	11e 235	Trp	Glu	Pro	Thr	11e 315	Glu	Asp
Asn	Val	Arg 250	Gln	Gly	Ala	Arg	11e 330	Val
Leu	Gly	Ala	Asp 265	Phe	Leu	Ala	Ser	Ala 345
Gln	Phe	Arg	Ala	Ser 280	Ser	Val	Tyr	Ala
Lys 215	Gln	Ala	Ser	Ala	G1n 295	Asp	Val	Ala
Ser	G1 y 230	Pro	Phe	Gly	Asn	Ala 310	Thr	Ala
Cys	Leu	Ala 245	Ala	Gly	Val	Asp	Thr 325	Ala
Thr	G 1y	Pro	Ala 260	Gly	Phe	Thr	Ala	Thr
Val	Gly	Glu	Phe	G1y 275	Val	Phe	Asn	Ala
Met 210	Leu	Val	Asp	Pro	Ser 290	Phe	Arg	Asn
Glu	Val 225	Ala	Thr	Arg	Glγ	G1y 305	Glu	Asp

Asp	Ala	Met 400	Lys	Pro	Ser	Pro	Phe 480	Thr	Arg	Pro
Arg	Val	Asn	Phe 415	Tyr	Pro	Ala	Arg	His 495	Asn	Ser
Gln	G1u	Leu	Val	Val 430	Thr	Val	Leu	Arg	Trp 510	Leu
Phe 365	G1 u	Trp	Gly	Ile	A1a 445	Ser	Ile	Ala	Lys	Leu 525
Ala	G1y 380	Pro	Arg	Leu	Ala	Ser 460	Arg	Leu	Ala	Arg
Phe	His	His 395	Asp	Pro	Ser	Phe	Arg 475	Tyr	Ala	Lys Arg
Gly	Val	Pro	Phe 410	Gly	Met	Leu	Asn	Thr 490	Gly	Pro
Glu	Arg	Val	Asp	Val 425	Gly	Leu	Gln	Lγs	Phe 505	Asp
Val 360	Asp	Arg	Ala	Ile	Asp 440	Ser	Glu	Tyr	His	Tyr 520
Tyr	Leu 375	Trp	Ile	Asp	Asp	Val 455	Gln	Gln	Arg	Lys
Ser	Phe	Leu 390	Arg	Thr	Trp	Ala	Leu 470	Ile	Val	Asn
Leu	Ala	Gly	Ser 405	Gly	Met	Tyr	Arg	G1y 485	Trp	Lys
Thr	Ala	Leu	Arg	Gln 420	Ser	Phe	Ala	Ala	Asp 500	Met
G1y 355	Tyr	Lys	Pro	Leu	Lys 435	Val	Leu	Leu	Ser	Glu 515
Leu	Ala 370	Asn	Val	Ile	Asn	Asp 450	Asp	Asp	Arg	Val
Val	Val	Leu 385	Phe	G1 y	Leu	G1u	Asn 465	Cys	Asp	Phe

Asn Phe Ile Asp Gln 530 Gly

6733 DNA <210><211><211><211><212><212><213>

mays Zea

S

gene (1)..(6733) <2220><2221><2222><2223><223>

for sedence genomic mays

from

oxidase

CDS (1497) <220><221><221><222>

(3216)CDS (2524) <2220><221><222>

(3607)CDS (3311) <2220><221><222>

20

unsure (5697) <220><221><221><222>

25

120 180 240 300 360 420 480 540 009 099 720 9 780 840 900 960 aaaaaaact acaacggctg tegtateace tagaatgcat agtccgtacg gtgtgcttct atggaaaacc ctagctatag tgccatttgc aacactaaca accgaacaaa agaaatctat atgagaagtt gctagcttga ggtcgtcgta tacagctgtc actagctgaa atatcttgga gatgtcattt gactcaaaat cagcattcgg cgaattccga actagacggt atggcatcaa tatacagacg ccttctctga tccaaaatgt gacgcgactt taaggtgaga, taaagcgaca atagcaaaat aataatcgtg accagctggg cgtaatgcag tgcttgagtc atttggatgg aattctacct attagtcatt aaatgacaaa ttactagaga tagctagcca cccaaatatg attgtttgtt aacgtatgtt gacatttttg aagtcgacca atatggccag tcgtcctgta ctgcgca tatatggatt cgtgcgtaga tttgttctat tggaaagaat tgttttactt aaaacatcag ttggac ggcagc gggacg gaaggctagc agtagt aaatcaaata ggctgt tgtattttgg ctgctttcct acaa atgc gcta gtgt tcat agg cgacgagagg acagtttggt ctactggtac gtatgatcta tgcgtgctaa ggaggagagg cctcaacatt aaacaacaaa tgaagttgac ggtcgtgtaa tcccaatcaa ctatattaat ataagatccc ttctggtagc atcagcttgg aaattacagc ctcgagactc gtaacttaaa aaccaaaatt ctatgtataa gtgtaagtca tgttgttcgt acactgaatt ccagccacac aatataattg gctggaaaaa tttgtacctt ttaatcaatc atatatgtat tggcagattg ttaaaccttc cgtagtacca

5

<400>

0

1070	1080	1140) r 	1200	1260	1320	1380	1440	9	1494 29		1547	1595	1643
agacggcctg	aatttgtaca	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	tattattaca	attaggcagg	taaagttggt	aactagacgg	aattgaagaa	ctaqttacca		tcgcta atg Met 1	-	tct cat Ser His	cgt ccc / Arg Pro	cggacc n Arg Thr
ataacataaa	ataqctacca		cgcttatatt	gggggtaata	gggaggatgg	aacagaataa	gtgttcgagt	. מיני אמר	grycaarcac	aacgacgacg		atc gcc tgc Ile Ala Cys 15	gat cgc ggc Asp Arg Gly 30	ggc aag ctc Gly Lys Leu 45
acattaagtg	a cacacat		aagaattgat	catggcaaca	gtaaattctt	tctqtggtca	geteatettt		tatatacggg	ctctcccgtg	. •	gcc ggg ctg Ala Gly Leu 10	ctc gga gac Leu Gly Asp	gcc ttg gac Ala Leu Asp
aggcacacac		gatatgytta	tttcattctc	cgctatattg	ttcttcttct	ogentatit		rrdgaaaysa	tacacctata	agctctctct		ctg ctg ctg (Leu Leu Leu 1	acg cct gcg Thr Pro Ala	gcc gcg ctg Ala Ala Leu 40
catttdadd		ataaccaaac	qcgaaaacta	tatataaata	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		Cttacttycy	attttttcc	gcactacacc	cataacgtat		tat tac Tyr Tyr	gca ggc Ala Gly	tcc ctc Ser Leu
	tagtagayat	attttatttc	actatttagt		gerrerada	actatatata	aactaggcac	gatgcagaat	gtatgtaatc	aacactcaca		gcg gtg gtt Ala Val Val	gca cta gcg Ala Leu Ala	tgg cca gcc Trp Pro Ala
			•					•						

1691	1739	1787	1835	1883	1931	1979	2027
acg Thr 65	ctg Leu	acc Thr	gcc Ala	gcg Ala	ggc G1y 145	ggc Gly	ggc Gly
atc Ile	gac Asp 80	tac Tyr	ttc Phe	gcc Ala	gcc Ala	cgc Arg 160	ggc Gly
aac Asn	ggc Gly	ccc Pro 95	gcc Ala	gcc Ala	gac	gcg Ala	gtc Val 175
99c 61y	acg Thr	tgg Trp	cag Gln 110	gac Asp	gtg Val	ctg	acc
ttc Phe	tcc Ser	999 61y	ggc Gly	ggc Gly 125	tac Tyr	Ser	ctc
gac Asp 60	tcg Ser	ccg Pro	atg Met	ctg Leu	cgc Arg 140	gcg Ala	tac Tyr
acg Thr	ccg Pro 75	acc Thr	ctc Leu	tcc Ser	ggc Gly	cgc Arg 155	ctc
tcg Ser	tac Tyr	tcc Ser 90	tcc Ser	gcg	gac Asp	ttg Leu	tac Tyr 170
gcc Ala	ctg Leu	aac Asn	cac His	atg Met	gcg Ala	gtg Val	gac Asp
gcg Ala	gtc Val	gcc Ala	ggc Gly	aac Asn 120	Ser	gac Asp	aac Asn
gcg Ala 55	gcg Ala	gcg Ala	cgc Arg	gtc Val	gtg Val 135	atc	tgg
acg Thr	9cg Ala 70	agc	ggc Gly	gtc Val	aac Asn	tgg Trp 150	Ser
gcg Ala	ccg Pro	ctg Leu 85	cgc Arg	gtc Val	atc	gtg Val	cgc Arg 165
Asn	ctc Leu	ctg Leu	ttc Phe 100	ggc Gly	cgc Arg	cag Gln	ocg Pro
agc Ser	gcg Ala	gcg Ala	gcg Ala	ggc Gly 115	ccg Pro	gag Glu	gcg Ala
gac Asp 50	tcg Ser	gtg Val	atc Ile	Pro	ccg Pro 130	ggc Gly	gtg Val
		•	•				

										•
c/07	2121	2181	2241	2301	2361	2421	2481	2535	2583	2631
acg ctg tcc aac gca ggc atc agc ggc cag gcg ttc cgc cac ggc cca Thr Leu Ser Asn Ala Gly Ile Ser Gly Gln Ala Phe Arg His Gly Pro 180	cag ata tot aac gtg ctg gag atg gac gtt atc acc ggtacgtgtg Gln Ile Ser Asn Val Leu Glu Met Asp Val Ile Thr 200	, מ	aaaqcttg	ס	tttatttt	. U		ttata	atg gtg acg tgc tcc aag cag ctg aac gcg gac ctg ttc gac gcc gtc Met Val Thr Cys Ser Lys Gln Leu Asn Ala Asp Leu Phe Asp Ala Val 210	ctg ggc ggg ctg ggg cag ttc gga gtg atc acc cgg gcc cgg atc gcg Leu Gly Leu Gly Gln Phe Gly Val Ile Thr Arg Ala Arg Ile Ala 230

	• .		· .				
2679	2727	2775	2823	2871	2919	2967	3015
acc Thr	cgg Arg	999 G1у	999 61y 305	gag Glu	gac Asp	gtg Val	gtg Val
tac Tyr	ccg Pro	gaa Glu	acg Thr	999 61y 320	tac Tyr	tcc Ser	gac Asp
gtg Val 255	gcc Ala	gtg Val	aac Asn	gcc Ala	aac Asn 335	gcg Ala	cgc Arg
ttc Phe	acc Thr 270	tac Tyr	gcg Ala	ctc Leu	ctc Leu	ctc Leu 350	cag Gln
cgg Arg	ctg Leu	agc Ser 285	ctg Leu	gcg Ala	acg Thr	gag Glu	ttc Phe 365
gtg Val	cgg Arg	atg Met	gac Asp 300	gtc Val	gcc Ala	cag Gln	gcg Ala
tgg Trp	gag Glu	ccg Pro	acc	atc ile 315	gag Glu	gac Asp	ttc Phe
cgg Arg 250	cag Gln	ggc Gly	gcg Ala	cgg Arg	atc Ile 330	gtg Val	999 G1у
gcg Ala	gac Asp 265	ttc Phe	ctg Leu	gcc Ala	agc Ser	gcg Ala 345	gag Glu
cgg Arg	gcc Ala	tcg Ser 280	agc Ser	gtc Val	tac Tyr	gcg Ala	gtg Val 360
gcg Ala	agc	gcg Ala	caġ Gln 295	gac Asp	gtg Val	gcg Ala	tac Tyr
ccg Pro	ttc Phe	ggc Gly	aac Asn	gcc Ala 310	acc Thr	gcg Ala	agc Ser
gcg Ala 245	gcg Ala	ggc Gly	gtg Val	gac Asp	acc Thr 325	gcg Ala	ctg Leu
ccg Pro	gcg Ala 260	ggc Gly	ttc Phe	acc Thr	gcc Ala	acg Thr 340	acg Thr
gag Glu	ttc Phe	99c G1y 275	gtg Val	ttc Phe	aac Asn	gcc Ala	ggc Gly 355
gtg Val	gac	ccc Pro	tcg Ser 290	ttc Phe	cgg	Asn	ctg

					·		
3063	3111	3159	3207	3256	3313	3361	3409
ctc Leu 385	ttc Phe	ggc Gly	ctc Leu	···•	atg Met	tac Tyr	agg Arg
gcg Ala	atg Met 400	aag Lys	ccc Pro		tttc	ttc Phe	gcg Ala
gtg Val	aac Asn	ttc Phe 415	tac Tyr	ggc		gtg Val	ctg
gag Glu	ctc Leu	gtg Val	gtc Val 430	ctagctag	gggtttggtt	gac Asp 450	gac Asp
gag Glu	tgg Trp	ggс G1у	atc Ile		gggt	gag Glu	aac Asn 465
99c 61y 380	ccg Pro	cgc Arg	ctc Leu	tagctag	tttctg	tct Ser	CCC Pro
cac His	cac His 395	gac Asp	CCG	O .	O	ccg Pro	gcg Ala
gtg Val	ccg Pro	ttc Phe 410	ggс G1у	გნ ა:	ggt	acg Thr	gtg Val
cgg Arg	gtg Val	gac Asp	gtc Val 425	cgat	gacc	gcg Ala 445	tcg Ser
gac Asp	cgg Arg	gcc Ala	atc Ile	gaat	acto	gcg Ala	tcg Ser 460
ctt Leu 375	tgg Trp	atc Ile	gac Asp	igt t	a cg	tcg Ser	ttc Phe
ttc	ctg Leu 390	cgc	acc Thr	acgt	tctg	atg Met	ctc Leu
gcg	999 61y	tcg Ser 405	ggc Gly	atgt	ငရွ်ရှင်င	ggc Gly	ctg Leu
gcg Ala	ctg Leu	cgc Arg	cag Gln 420	tcc Ser	gc	gac Asp 440	tcg Ser
tac Tyr	aag Lys	ccg Pro	ctg Leu	aaa Lys 435	ნაააა	gac Asp	gtg Val 455
gcc Ala 370	aac Asn	gtg Val	atc Ile	aac Asn	>	tgg Trp	gcg. Ala

	.0	m	_	~	_	_	7	7		7	7
3457	3505	3553	3601	3657	3717	3777	3837	3897	3957	401	4077
ддд Gly 485	tgg Trp	аад Lys	ttc	taa	tgatgtatgt	ttctcgtttc	caccgttt	laaattt	aacaaaagga	tgatatagtt	gtccaaaatc
gcc Ala	gac Asp 500	atg Met	atc	atgtgaataa	tgat	ttct	caca	gaca	aaca	tgat	gtco
ctc Leu	agt Ser	gag Glu 515	gac Asp	atg'			to			ggta	
gac Asp	cgc Arg	gtg Val	cag Gln 530	aata	atcactgcac	tcgtcgtata	gcaaaatt	tatatagcaa	agaataaccg	ttag	cctaataggc
tgc Cys	gac	ttc Phe	ggc Gly	tgggacaata	atc	tcgt	gca	tat	aga	tattta	ccti
ttc Phe 480	acg	cgc Arg	ccc Pro		attg	gtacco	gaga	taaa	tgaaatt	tgcc	ctgtcgt
cgc Arg	cac His 495	aat Asn	tcc Ser	tttagtttct	tatagattg	aaagt	cacgttgaga	tccgtataaa	atga	tttgtgtgcc	
ctg Leu	cgg Arg	tgg Trp 510	ctc Leu	tagt	Ø	ď		a tc	c aca	t tt	m t C
atc Ile	gcg Ala	aag Lys	ctg Leu 525		ctgt	aaaaa	aaatg	Ø	aatt	cttt	ataci
agg Arg	ctg Leu	gcc	agg Arg	ccatgcatgt	attaatctgt	tggtaa	tttaaaa	gtatattg	cat	ttgca	gtcaaataca
agg Arg 475	tac	gcc	aag Lys	cato	๙				ac ac		
aac Asn	acc Thr 490	ggc Gly	ccc Pro		statt	acgt1	cagagt	ttgggt	tcccgtac	ttgc	ttga
cag Gln	aag Lys	ttc Phe 505	gac	tgatagc	qeqqeta	atttacgtta	2222	taga	gato	tagattgaag	ttatttgaca
gag Glu	tac Tyr	cac His	tac Tyr 520	tgat	ಹ	ند	તા	ag	ىد		р В В
cag Gln	cag Gln	cgc	aag Lys	tga	ttoccadct	ggtcatt	taccc	, catqtag	attocaatc	cttattagta	ctgccaaaca
ctg Leu 470	atc Ile	gtc Val	aac	aac	1	Caa Oaa	1	τ Ω		, t	ctg

ctttgccttc

tccctatttt

5037 5097 4917 4317 4437 4497 4557 4677 4737 4797 4857 4617 4257 4197 gctcccatcg tegttttete aggtcactcc tacaccgatt acgacgagaa acggagggag tgactagtgg agattattgg acttattatt cttgttgatc aggtcggctg attgattctt ttttaaatca ctagtcactt gcttcgatct aaacaaatta ggataattag caggagacag agtagacacc aaatgtataa attaatgata atagcaggat ttgttccgtg ggtgtcatat cttaattcga ccgtacacgt cttttagacg aggtggtcgt cgcgaccagc tggtcctcaa gtcacttgtg tgcacgtttt acgaagtaac caagctacac tgattcccag caacaagcct tgcggtgtgc cacttgcaag gaataaataa atacgaaacc aaaaataaac tctctcaccc aaaagacacc gggtcatttg taaccagtag tatttattta tcataataaa cacgcccata aaataataac ccccttgag agtttt gcactg tttgat tgacct agggaaatga cacacg cgcgtgatac cagaag aacaaa tcaaaa ggtaaa cccatccaaa tttcctcttc aggagaagga tacaaa taatga gttt tttc ttca aacti ttat acat gtgc caca ataa tgac agacgaacga tcaa atccttaaga gtaccccggt gcttggtgag cgtcacaggt aatagaaaa accgctagtc agcgttcacc ctaagcaacg cgtcgacaag acatcaagtg ttagccagcc aaaagtttct tggatcgagg gattctttta cgtccgtcat tttgttttt aagagtgtga agtattgtct atcatcggga acaaaaaag ttatagccgt ggcaatgcta agacagctga tactagctta ttgtttcctc agcacagact ttaaacttta gttttgaata aaacgtgtgt ccgacggcac gtgttgaact ccttttaatt aaaaaaagg

01

S

30

25

5217

5277

5337

5397

5457

5517

5577

5637

5697

5757

5877

5937

5997

20

ttctaaatac tacgaaatt ataaaatggt aagacctctt ataacaggac ggacaatcga cctcctqttt gactagcttt ataaattcaa attttcttgn cgactattt acggtgaytc tacaacgtat gagaagataa ggaggcagtt aacttcactc ytccacacgg ggtgtttggt tgtactgtga aattatcaaa ctagaatgga cctttattag ctatgtgtgt tgtatttact acttataaaa tgttagagta ataaaaacac gaatataaat tactaatgtt aatctgttta tttttgggac amgtgtttgt ttcttggcgc tctgcattca acggacaatc aaaacatggg tgtcattccc gatttgtaag aatttatgta ctagtcacta ctcaacatgc atgtgtaaca tgtatatatg catgtaatat catcaaagtt ttttaaaaaa aatgacatta gagaaattat ttttataata aaataaactt tggtcatctg acgctattgt agtattttgt cagctgtagg tacgtatgaa ttattatatt aaaaatcaaa attattaggc agttgtacgt tatttatgtc yttagt laaaat ttagaaatg ttagtcacat ttatatcctc tctag cgatactaat ggtgg laggct tatat ctaac aatag acaag gaatc tgaaa tattc tcaaa ttaam ccactcttta ctggacacgt agctgcacgt tttaatttta attagtccct cccaaacttc gtcgcgatgg tgatctattt aataatataa acatatttga tgaagtttaa aataaataat atataaatta gactccttgt gagtacatat acgtaacatg gccgggggcg cgtgcaaacc gacgtcattt taatttttag aaaatagatt gtgattaaaa tctcaaacgt gagcaagcta aaccaggccc taaatcagtt aaaatagata tattttctac cgtactacgt catttgtaaa gatgaggatt

)					aagett	cataatcoda
7179	aaccctgcaa	agtgtgcgca	catgccgaag	caactcggtg	ggcgtcttcc	caagagaact
7600	ggagggagca	ttgctgttgt	gcggacgcga	agtcgagcaa	cacgatggca	attatgcact
7800	ataaaaaaaa	gatgaaactg	tctatctgat	gagcggtttg	accactgagc	tcagtaagga
000	agagctcctt	aggcaaatgc	gatggtaacc	gaacctgaaa	caatcccgtc	aacagtgttc
04//	cttcgtggac	tcctaacttc	agctcgatgg	accagccgca	agagcagccc	tctccggtga
7 7 7 7	gccggagcag	ctttcagctc	cacctccaca	cttgggcgcc	cctcctagtc	tcagctactg
6357	ttgatgcaca	gctacactat	tgaggctaca	tattcttcaa	cagtggctat	tggagcacgt
6297	aatacaatga	catggaaacg	ccataattta	gggggagcag	tacatcatca	ccgtatgtgc
6237	acaaaattgg	ttgcatcttc	gataccaggg	gtgggaacat	agggagacgc	gggcagttaa
	receasy rea	acggcacyca	gaacacggac	ggatgggcat	gtgtttttct	ccatacgcac

<210> 3 <211> 1605 <212> DNA <213> Zea mays <220> <221> CDS <221> CDS <222> (1)..(160

48	96	144	192	240	288	. 336	384
tct Ser	cgt	cgg Arg	atc Ile	gac Asp 80	tac Tyr	ttc Phe	gcc Ala
tgc Cys 15	ggc Gly	ctc Leu	aac Asn	ggc Gly	ccc Pro 95	gcc Ala	gcc Ala
gcc Ala	cgc Arg 30	aag Lys	ggс G1у	acg Thr	tgg Trp	cag Gln 110	gac Asp
atc Ile	gat Asp	99c G1y 45	ttc Phe	tcc Ser	999 61y	ggc Gly	99c 61y 125
ctg Leu	gac Asp	gac Asp	gac Asp 60	tcg	ccg Pro	atg Met	ctg
999 G1y	gga Gly	ttg Leu	acg Thr	ccg Pro 75	acc Thr	ctc Leu	Ser
gcc Ala 10	ctc Leu	gcc Ala	tcg Ser	tac Tyr	tcc Ser 90	tcc Ser	gcg Ala
ctg Leu	gcg Ala 25	ctg Leu	gcc Ala	ctg Leu	aac Asn	cac His	atg Met
ctg Leu	cct Pro	gcg Ala 40	gcg Ala	gtc Val	gcc Ala	ggc Gly	aac Asn 120
ctg Leu	acg Thr	gcc Ala	gcg Ala 55	gcg Ala	gcg Ala	cgc Arg	gtc Val
tac Tyr	ggc Gly	ctc Leu	acg Thr	gcg Ala 70	agc Ser	ggc Gly	gtc Val
tat Tyr 5	gca Ala	tcc Ser	gcg Ala	ccg Pro	ctg Leu 85	cgc Arg	gtc Val
gtt Val	gcg Ala 20	gcc Ala	aac Asn	ctc Leu	ctg Leu	ttc Phe 100	ggc Gly
gtg Val	cta Leu	cca Pro 35	agc Ser	gcg Ala	gcg Ala	gcg Ala	ggc G1Y 115
0> 3 gcg Ala	gca Ala	tgg Trp	gac Asp 50	tcg Ser	gtg Val	atc	CCC Pro
<400 atg Met 1	cat His	CCC Pro	acc Thr	acg Thr 65	ctg Leu	acc Thr	gcc Ala
		-					

gcc gac Asp gtg Val tac Tyr cgc Arg 140 99c Gly gac Asp gcg Ala tcc Ser gtg Val 135 aac Asn atc Ile cgc Arg ccg ccg Pro 130

> gcg Ala

						•	•
480	528	576	624	672	720	768	816
cgc Arg 160	ggc Gly	ggc Gly	999 Gly	gcc Ala	atc Ile 240	tac Tyr	ccg Pro
gcg Ala	gtc Val 175	cac His	cat His	gac Asp	cgg Arg	gtg Val 255	gcc Ala
ctg Leu	acc	cgc Arg 190	ggc Gly	ttc Phe	gcc Ala	ttc Phe	acc Thr 270
tcg Ser	ctc Leu	ttc Phe	acc Thr 205	ctg Leu	cgg Arg	cgg Arg	ctg Leu
gcg Ala	tac Tyr	gcg Ala	atc Ile	gac Asp 220	acc Thr	gtg Val	cgg Arg
cgc Arg 155	ctc Leu	cag	gtt Val	gcg Ala	atc Ile 235	tgg Trp	gag Glu
ttg Leu	tac Tyr 170	ggc Gly	gac Asp	aac Asn	gtg Val	cgg Arg 250	cag Gln
gtg Val	gac Asp	agc Ser 185	atg Met	ctg Leu	gga Gly	gcg Ala	gac Asp 265
gac Asp	aac Asn	atc Ile	gag Glu 200	cag Gln	ttc Phe	cgg Arg	gcc Ala
atc	tgg Trp	ggc 61у	ctg Leu	aag Lys 215	cag Gln	gcg Ala	agc Ser
tgg Trp 150	tcc Ser	gca Ala	gtg Val	tcc Ser	999 61y 230	ccg Pro	ttc Phe
gtg Val	cgc Arg 165	aac Asn	aac Asn	tgc Cys	ctg Leu	gcg Ala 245	gcg Ala
cag Gln	ccg Pro	tcc Ser 180	tct Ser	acg Thr	999 Gly	ccg Pro	9cg Ala 260
gag Glu	gcg Ala	ctg Leu	ata Ile 195	gtg Val	ggс G1у	gag Glu	ttc Phe
ggc Gly	gtg Val	acg Thr	cag	atg Met 210	ctg Leu	gtg Val	gac Asp
99c 61y 145	ggc Gly	ggc Gly	cca Pro	gag Glu	gtc Val 225	gcg	acc Thr

4	7	0	80	56	0 4		00
98	91	96	100	10	11	11	12
gaa Glu	acg Thr	999 619 320	tac Tyr	Ser	gac Asp	gcg Ala	atg Met 400
gtg Val	aac Asn	gcc Ala	aac Asn 335	gcg Ala	cgc Arg	gtg Val	aac Asn
tac Tyr	gcg Ala	ctc Leu	ctc Leu	ctc Leu 350	cag	gag Glu	ctc Leu
agc Ser 285	ctg Leu	gcg Ala	acg Thr	gag Glu	ttc Phe 365	gag Glu	tgg Trp
atg Met	gac Asp 300	gtc Val	gcc Ala	cag Gln	gcg Ala	990 61y 380	ccg Pro
ccg	acc Thr	atc Ile 315	gag Glu	gac Asp	ttc Phe	cac His	cac His 395
ggc Gly	gcg Ala	cgg Arg	atc 11e 330	gtg Val	999 Gly	gtg Val	ccg Pro
ttc Phe	ctg Leu	gcc	agc Ser	gcg Ala 345	gag Glu	cgg Arg	gtg Val
tcg Ser 280	agc Ser	gtc Val	tac Tyr	gcg Ala	gtg Val 360	gac Asp	cgg
gcg Ala	cag Gln 295	gac Asp	gtg Val	gcg Ala	tac Tyr	ctt Leu 375	tgg Trp
ggc Gly	aac Asn	gcc Ala 310	acc Thr	gcg Ala	agc	ttc Phe	ctg Leu 390
ggc G1у	gtg Val	gac Asp	acc Thr 325	gcg Ala	ctg Leu	gcg Ala	999 61y
ggc Gly	ttc Phe	acc	gcc Ala	acg Thr 340	acg Thr	gcg Ala	ctg Leu
ggc G1y 275	ם ע	ttc Phe	aac Asn	gcc Ala	990 61y 355		aag Lys
CCC Pro	tcg Ser 290	T t	cgg Arg	aac Asn	ctg Leu	gcc Ala 370	ส ญ
cgg Arg	999 G1y	999 Gly 305	gag Glu	gac Asp	gtg Val	gtg Val	ctc
							•

1248	1296	1344	1392	1440	1488	1536	1584
aag Lys	CCC	tct Ser	ccc Pro	ttc Phe 480	acg	cgc Arg	ccc Pro
ttc Phe 415	tac Tyr	ccg Pro	gcg Ala	cgc Arg	cac His 495	aat Asn	Ser
gtg Val	gtc Val 430	acg Thr	gtg Val	ctg Leu	cgg Arg	tgg Trp 510	ctc Leu
ggc Gly	atc Ile	gcg Ala 445	tcg Ser	atc Ile	gcg Ala	aag Lys	ctg Leu 525
cgc Arg	ctc Leu	gcg Ala	tcg Ser 460	agg Arg	ctg Leu	gcc Ala	agg Arg
gac Asp	ccg Pro	teg Ser	ttc Phe	agg Arg 475	tac Tyr	gcc Ala	aag Lys
ttc Phe 410	ggc Gly	atg Met	ctc Leu	aac Asn	acc Thr 490	ggc Gly	ccc Pro
gac Asp	gtc Val 425	ggc Gly	ctg Leu	cag Gln	aag Lys	ttc Phe 505	gac Asp
gcc Ala	atc Ile	gac Asp 440	tcg Ser	gag Glu	tac Tyr	cac His	tac Tyr 520
atc	gac Asp	gac Asp	gtg Val 455	cag Gln	cag Gln	cgc Arg	aag Lys
cgc Arg	acc Thr	tgg Trp	gcg Ala	ctg Leu 470	atc Ile	gtc Val	aac Asn
tcg Ser 405	ggc Gly	atg Met	tac Tyr	agg Arg	999 G1y 485	tgg Trp	aag Lys
cgc Arg	cag Gln 420	tcc Ser	ttc Phe	gcg Ala	gcc Ala	gac Asp 500	atg Met
ccg Pro	ctg Leu	aaa Lys 435	gtg Val	ctg Leu	ctc Leu	agt Ser	gag Glu 515
gtg Val	atc Ile	aac Asn	gac Asp 450	gac Asp	gac Asp	cgc Arg	gtg Val
ttc Phe	ggc G1y	ctc Leu	gag Glu	aac Asn 465	tgc Cys	gac Asp	ttc

V

0

15

tg aac Asn ttc Phe atc Ile gac Asp cag Gln 530 ggc Gly

4 21 PRT Zea <210><211><211><211><212><213>

mays

VARIANT

(6) <2220><221><222>

10

Ph Val Ser 5 Gly Glu)> 4 Val <400> Tyr 1

Phe G1y 20 Thr Asn Ala

mays 5 15 PRT Zea <210><211><211><211><212><212><213>

Asp Thr Leu Gln Gly 5 **Gly**

20

က

<220>
<221> modified_base
<222> (15)
<223> i
<220>
<221> modified_base
<221> modified_base
<222> (18)
<2223> i

<400> 6 tacgtngayg gnwsngtntt cgt

25

<210> 7
<211> 23
<211> 23
<212> DNA
<213> Zea

mays

modified_base (6)

<220><221><222><222><223>

mays

6 23 DNA Zea

<210><211><211><211><211><212><213><

modified base

(12) i

<220><221><221><222><222><223>

cnaacacngg ntt modified_base (21) i modified_base (3) base base base modified_ (12) i modified_ (18) i mays modified_ (9) i acngayctng 8 23 DNA 2ea <210><211><211><211><212><212><213> <400> <220><221><221><222><222><223> <220><221><222><222><223><223> <220><221><221><222><222><223> <2220><221><2222><222><223> <2220><2221><2222><2223><223> 30

15

10

rta

tecentgnet modified_base (15) i modified_base (18) base base base modified_ (9) i modified modified_ (6) i mays ccntargang (3) Zea DNA 23 ∞ <220><221><221><222><222><223> <220><221><221><222><222><223> <220><221><221><222><222><223> <220><221><222><222><223> <400> <211><211><212><213> <210> <220><221><221><222><222><223>

10

15

20

modified_base (21) modified_base (15) modified_base (12) modified_base (9) variation (6) Zea mays 10 1602 tarcanceng DNA $\boldsymbol{\omega}$ <2220><221><2222><222><223> <210><211><211><211><212><213> <400> <2220><221><2222><222><223> <2220><221><2221><2222><2223> <2220><221><2221><2222><2223></223> <2220><221><2222><222><2223> 30 25 20 10 5

gngantarca nat

or

a,g,c

<220>
<221> variation
<222> (9)
<2223> a,g,c or t
<222> variation
<222> (12)
<222> (12)

5

<220> <221> variation <222> (21) <223> a,g,c or t

<220> <221> variation <222> (24) <223> a,g,c or t

<220> <221> variation <222> (27) <223> a,g,c or t

<220> <221> variation <222> (30) <223> a,g,c or t

<220> <221> variation <222> (33)

30,

Ţ a,g,c.or <223>

variation (36) <220><221><2221><222><222><223>

a,g,c

Ų

or

variation (42) or a,g,c <2220><221><2222><222><223>

u

variation (48) or a,g,c <2220><2221><2222><2223><223>

variation (54) Or a,g,c <220><221><2221><2222><2223></223>

variation (57) <220><221><221><222><222><223>

or a,g,c

Ţ

variation (60) or a,c,g <220><221><221><222><222><223>

1200

30

5

10

20

15

variation (63) variation (66) variation (69) variation (72) variation (75) variation (78) or or or or or a,g,c a,g,c O a,g,c a,g,c a,g,c a,g, <220><221><221><222><222><223> <220><221><222><222><222><223> <220><221><222><222><223> <220><221><221><222><222><223> <2220><2221><2222><2223><2223> <220><221><222><222><223>

2

)

15

20

25

variation (105)

<220><221><221><222><222><223>

a,g,c

variation (81)	,	(90) a,g,c or t	variation (93)	5	variation (96) a,g,c or t	variation (99) a,g,c or t
<221> <222>	220	<222> <222> <223>	<220><221><221><221><222>	223 223 220	<221> <222> <222> <223>	<220><221><221><222><222><223>
	S .	•	<u> </u>	15		20

variation (114) a,g,c or t

<220><221><2222><222><223></223>

variation

or

(117) a,g,c

20

25

ļ

or

a,g,c

variation (123)

<2220><221><2221><2222><2223>

variation

<220>

OK

(120) a,g,c

<221><222><222><223>

<220><221><221><222><222><223>

u

variation (111) a,g,c or t

<220><221><222><222><222><223>

variation (108) a,g,c or t

<220><221><221><222><222><223></223>

5

. ~ ~ .

20

variation (147) ų variation (129) a,g,c or t variation (141) variation (135) a,g,c or t variation (126) a,g,c or t variation OI or or a,g,c a,g,c a,g,c (144)<2220><221><2221><2222><2223> <220><221><221><222><222><223> <220><221><221><222><222><223> <220><221><222><222><223><223> <2220><221><2222><2223><2223> <2220><221><2222><222><223>

S

variation (159) or a,c,g <2220><2221><2222><2223><2223>

variation (162) a, g, c or t <220><221><222><222><222><223>

variation (165) Or a,g,c <220><221><222><222><223>

<220><221><222><222><223>

variation (168) or a,g,c

variation (171) or a,g,c <220><221><222><222><223>

5

variation (153) a,g,c or t

<220><221><221><2222><222><223>

20

t Ţ t variation (195) variation (201) variation (198) a,g,c or t variation (186) a,g,c or t variation (174) a,g,c or t variation (177) or or or a,g,c a,g,c a,g,c <220><221><221><222><222><223> <2220><2221><2222><2223><223> <220><221><221><222><222><223> <220><221><221><222><222><223> <2220><221><2221><2222><2223> <220><221><222><222><222><223>

10

5

25

variation (207) variation (213) variation variation (219) variation variation or or or OL or or a,g,c a,g,c a,g,c (204)a,g,c a,g,c a,g,c (210)(216)<220><221><221><222><222><223> <220><221><222><222><223> <220><221><222><222><222><223> <220><221><222><222><222><223> <220><221><221><222><222><223> <2220><2221><2222><2223><2223>

5

10

15

20

variation (237) variation (243) variation (231) variation (234) variation (228) variation (225) a,g,c or t OH or OL or or a,g,c a,g,c a,g,c a,g,c a,g,c <220><221><221><222><222><223> <220><221><221><222><222><223> <220><221><221><222><222><223> <220><221><222><222><222><223> <2220><2221><2222><2223><2223> <2220><2221><2222><2223>

10

5

25

variation (249) variation (252) a,g,c or t variation (255) variation variation (258) a,g,c or t variation (261) OL or or or a,g,c a,g,c (246)ρ a,g,c a, c, <220><221><221><222><222><223> <220><221><222><222><223></223> <220><221><222><222><222><223> <220><221><222><222><222><223> <220><221><221><222><222><223> <2220><2221><2222><2223><2223>

10

5

15

20

¥ ¥ variation (276) variation (273) variation (270) variation or or OL a,g,c a,g,c a,g,c (264)<2220><2221><2222><2223><2223> <2220><2221><2222><2223><2223> <220><221><221><222><222><223> <2220><2221><2222><2223><2223>

5

variation (285) or a,g,c <220><221><221><222><222><223>

variation (279) a,g,c or t

<220><221><221><2222><222><223>

20

OL

a,g,c

25

÷

variation (291) a,g,c or t variation (297) a,g,c or t <220><221><221><222><222><223> <220><221><221><222><222><223>

5

variation (303) a,g,c or t <220><221><221><222><222><223>

10

<220><221><222><222><223>

variation (306) a,g,c or t

variation (309) OL a,g,c <220><221><221><222><222><223>

variation (312) a,g,c or t <220><221><221><222><222><223>

... **ند**

4 4 variation (342) variation (339) 4 variation (333) variation (327) variation (321) variation or Or or or or OL a,g,c a,g,c a,g,c a,g,c a,g,c a,g,c (318)<220><221><222><222><223></223> <2220><221><2221><2222><2223></223> <220><221><222><222><223></223> <220><221><221><222><222><223> <2220><221><2222><222><2223> <2220><2221><2222><2223><2223>

10

5

15

20

4 variation (345) or a,g,c <220><221><222><222><223></223>

variation (348) or a,g,c <220><221><222><222><222><223>

variation (351) a,g,c or t <220><221><2221><2222><223>

variation (354) a,g,c or t <220><221><222><222><223></223>

variation (357) a,g,c or t <220><221><221><222><222><223>

variation (366)

or a,c,g <220><221><222><222><222><223>

20

variation (381) variation (372) variation variation OF OL or or a, g, c a,g,c a,g,c a,g,c (375)(369)<2220><2221><2222><2223><2223> <2220><221><2221><2222><223> <2220><221><2222><222><223> <2220><221><2221><2222><2223> 15 10 S

<220> variation <221> variation <222> (384) <223> a,g,c or t <220> <221> variation <221> variation <222> (387) <222> <387)

20

.

variation (390) variation (393) variation (396) a,g,c or t variation (405) ¥ variation (408) variation (411) a,g,c or t or or or or a, g, c a,g,c a,g,c a,g,c <220><221><221><222><222><223> <220><221><222><222><222><223> <220><221><222><222><223>< <220><221><222><222><223> <220><221><222><222><223> <2220><2221><2222><2223><2223>

5

CIRCTITITE CUEET (mile 36)

20

¥ variation (438) a,g,c or t variation (435) variation (426) variation (420) variation (417) a, g, c or t variation OK or or or a,g,c a,g,c a,g,c a,g,c (432) <2220><2221><2222><222><223> <2220><221><2221><2222><2223><2223> <2220><2221><2222><2223><2223> <220><221><221><222><222><223> <220><221><221><222><222><223> <2220><2221><2222><2223><2223>

10

9

variation (447) variation (459) variation (462) a,g,c or t variation (465) variation (468) Or or Or a,g,c a,g,c a,g,c <220><221><222><222><223> <220><221><222><222><223> <220><221><222><222><223> <2220><221><2222><222><2223> <2220><2221><2222><2223><2223>

variation (471) or a,g,c <220><221><221><222><222><223>

or

a,g,c

2

15

20

¥ variation (486) variation (477) variation (483) variation variation OK variation or OI or OL (489) a,g;c a,g,c a,g,c a,g,c a,g,c a,c,g (480)(474)<2220><221><2221><2222><223> <2220><221><2221><2222><2223><2223> <220><221><221><222><222><223> <2220><2221><2222><2223><2223> <2220><2221><2222><2223><2223> <2220><221><2222><2223><223>

5

15

u variation (492) variation (495) a,g,c or t variation (498) a,g,c or t variation (513) variation (522) a,g,c or t variation or OR or a,g,c U (519)a, g, a,g, <2220><2221><2222><2223><2223> <220><221><221><222><222><223> <220><221><222><222><223> <2220><2221><2222><2223><2223> <220><221><222><222><222><223> <2220><2221><2222><2223><2223>

10

S

20

variation	(525) a,g,c or	
<2221>	<222> <223>	

variation (528) Or a,g,c <221><222><222><223> <220>

u variation (531) or a,g,c <2220><2221><2222><2223><2223>

٠ 🗘 variation OL a,g,c (534)<2220> <2221> <2222> <223>

variation (537) or a,g,c <220><221><2221><2222><2223>

variation OI (540) a,g,c <220><221><221><222><222><223>

variation (546) a,g,c or t <220><221><2221><2222><2223>

variation (549) or a,g,c <220><221><221><222><222><223>

variation (555) a,g,c or t <220><221><222><222><222><223>

variation (558) a,g,c or t <220><221><222><222><222><223>

variation or a,g,c (564)<220><221><221><222><222><223>

variation (570) a,g,c or t <220><221><221><222><222><223>

1

2

10

15

20

ى	
ion or	-
variat (576) a,g,c	
<220><221><222><222><223> 223	<220>

S

variation (618) a,g,c or t

<220><221><221><222><222><223>

5

variation (615)

<220><221><221><222><222><223>

or

a,g,c

variation (633) a,g,c or t

<2220><2221><2222><2223><2223>

20

variation (637) a,g,c or t

<2220><2221><2222><2223><2223>

variation (642) a,g,c or t

<220><221><222><222><222><223>

variation (624) a,g,c or t

<220><221><221><222><222><223>

CIDCTITUTE CITTIET / SALL OC)

20

variation (678) variation (675) ¥ variation (657) variation (651) variation variation or or or or or or a,g,c a,g,c a,g,c a, g, c a,g,c (672)a,g,c (663) <221><222><222><223> <220><221><222><222><222><223>< <2220><2221><2222><2223><2223> <2220><2221><2222><2223><2223> <220> <221><222><222><223> <220><221><221><222><222><223> <220>

10

S

variation (684) variation variation (687) variation (699) a,g,c or t variation Or Or or or a,g,c a,g,c (681) a,g,c (690) a,g,c <220><221><222><222><223> <220><221><221><222><222><223> <220><221><222><222><222><223> <220><221><222><222><223></223> <2220><2221><2222><2223><2223>

10

5

15

variation (702)

<220><221><221><222><222><223>

or

a,g,c

<220>
<221> variation
<222> (708)
<2223> a,g,c or t
<220>
<220>
variation

9

<220>
<221> variation
<222> (711)
<223> a,g,c or t

<220> <221> variation <222> (717) <223> a,g,c or t

10

<220>
<221> variation
<222> (723)
<223> a,g,c or t

15

<220> <221> variation <222> (726) <223> a,g,c or t

20

<220> <221> variation <222> (732) <223> a,c,g or t

variation (738) variation (735) variation (741) variation (744) variation (747) variation (750) Or Or or OK Or a,g,c a,g,c a,g,c a,g,c a,g,c a,g,c <2220><2221><2222><2223><2223> <220><221><222><222><223> <220><221><222><222><222><223> <2220><2221><2222><2223><2223> <2220><221><2221><2222><2223></223> <220><221><221><222><222><223>

S

10

15

20

<220>
<221> variation
<222> (756)
<222> (756)
<223> a,g,c or t
<221> variation
<222> (759)
<222> (759)
<222> (759)
<222> (759)
<222> (765)
<222> (765)
<222> (765)

<222> (765) <223> a,g,c or t <220> <221> variation <222> (771) <223> a,g,c or t

<221> variation <222> (780) <222> (780) <223> a,g,c or t <221> variation <222> (783) <223> a,g,c or t

20

. . .

variation (789) a,g.c or t 4 variation (792) variation (804) variation (807) variation (810) variation (813) or or or or or a,g,c a,g,c a,g,c a,g,c a,g,c <220><221><222><222><223></223> <220><221><222><222><223></223> <2220><2221><2222><2223><2223> <2220><2221><2222><2223></2223> <2220><221><2222><2223><2223> <2220><2221><2222><2223><2223>

5

10

15

20

	_		11	
	tion		or	
	d	(816)	a,g,c	
<220>	2	<222>	7	

or

a,g,c

variation (834) variation (837) a,g,c a,c,g <220><221><222><222><222><223> <220><221><221><222><222><223> 5 10

OL

u

or

variation or a,g,c (840) <220><221><222><222><223>

variation (846) or a,g,c <220><221><222><222><223>

15

variation or O (849) a,g, <220><221><221><222><222><223>

20

variation (855) a,g,c or t <2220><2221><2222><2223><2223>

25

variation OL a,g,c (861)<2220><2221><2222><2223><2223>

Ţ variation (867) or a,g,c <220><221><222><222><223><223>

5

variation <220><221><221><222><222><223>

10

variation (873) or or a,g,c a,g,c (870) <220><221><221><222><222><223>

variation (879) or a,g,c <220><221><221><222><222><223>

20

variation (888) OK a,g,c <2220><2221><2222><2223><223>

4 variation (891) a,g,c or t variation (894) a,g,c or t <220><221><222><222><222><223> <2220><2221><2222><2223><2223>

¥ variation (897) a,g,c or t <2220><2221><2222><2223><2223>

variation (903) or a,g,c <2220><221><222><222><222><223>

<2220><221><2222><2223><2223>

variation (906) a,g,c or t

variation (912) or a,g,c <220><221><221><222><222><223>

u

5

15

20

20

بد ų ىد variation (939) 4 variation (936) variation variation (924) variation OR variation or or OK OI 20 (942) a,c,g a,g,c a,g,c a,g,c a,g,c (930) a,g,c (915)<2220><2221><2222><222><223> <2220><2221><2222><2223><2223> <2220><2221><2222><2223><2223> <2220><2221><2222><2223><2223> <220><221><222><222><222><223> <2221><222><2223> <220>

10

S

<221> variation <222> (948) <223> a,g,c or

<220>

<220> <221> variation <222> (951) <223> a,g,c or t

<220>
<221> variation
<222> (954)
<223> a,g,c or t

<221> variation <222> (957) <223> a,g,c or t

<220>
<221> variation
<222> (960)
<223> a,g,c or t

<220>
<221> variation
<222> (966)
<223> a,g,c or t

20

25

=

Ś

10

15

<220>
<221> variation
<222> (972)
<222> a,g,c or t
<220>
<221> variation
<222> (975)
<222> (975)

S

<220>
<221> variation
<222> (978)
<223> a,g,c or t
<220>

<220>
<221> variation
<222> (987)
<223> a,g,c or t

<220>
<221> variation
<222> (996)
<223> a,g,c or t

20

<220> <221> variation <222> (999) <223> a,g,c or t

÷

variation (1017) variation (1020) variation (1023) variation (1029) variation variation or or or or OL or (1002)(1026)a,g,c a,g,c a,g,c a,g,c a,g,c a,g,c <220><221><221><222><222><223> <220><221><222><222><222><223><223> <2221><222><222><223> <2220><2221><2222><2223><2223> <220> <2220><2221><2222><2223></2223> <2220> <221> <222> <223>

V

10

15

20

OI

a,g,c

variation (1038) variation (1035) variation (1032) Or or a,g,c a,g,c <220><221><221><222><222><223> <220><221><221><222><222><223> <220><221><221><222><222><223>

ų variation (1050) or a,g,c <220><221><222><222><223>

variation (1053) Or a,g,c <2220><221><2221><2222><2223><2223>

or: t variation (1056) a,g,c <2220><221><222><222><222><223>

5

10

20

<220>
<221> variation
<222> (1059)
<223> a,g,c or t

<220>
<221> variation
<222> (1062)
<223> a,c,g or t

<220>
<221> variation
<222> (1065)
<223> a,g,c or t

<220>
<221> variation
<222> (1068)
<223> a,g,c or t

<220> <221> variation <222> (1071) <223> a,g,c or t

<220> <221> variation <222> (1074) <223> a,g,c or

.. 20

5

 \simeq

<221> variation <222> (1080) <223> a,g,c or t	<220> <221> variation <222> (1086) <223> a,g,c or t	<220> <221> variation <222> (1092) <223> a, g, c or t
	S .	10

<220>

<221> variation <222> (1101) <222> (1101) <223> a,g,c or t <221> variation <222> (1107) <223> a,g,c or t <220> <221> variation <222> (1110) <222> (1110) <222> (1110)

<221> variation <222> (1116) <222> (1116) <223> a,g,c or t <222> (1119) <222> (1119) <222> (1125) <221> variation <222> (1125) <222> (1125) <222> (1125)

5

<220>
<221> variation
<222> (1131)
<222> a,g,c or t
<221> variation
<222> (1134)
<222> (1134)
<222> (1140)
<222> variation

10

20

<220> <221> variation <222> (1149) <223> a,g,c or t	<220> <221> variation <222> (1152) <223> a,g,c or t	<220> <221> variation <222> (1155) <223> a,g,c or t	<220> <221> variation
	v o	10	15

<221> variation
<222> (1164)
<222> (1164)
<223> a,g,c or t
<222> (1167)
<222> (1167)
<222> (1167)
<222> (1170)
<222> (1170)
<222> (1170)

20

25

÷

H variation (1182) variation (1188) variation (1209) variation (1194) a,c,g or t variation (1206) variation OR OK or or or (1176)agge a,g,c a,g,c a,g,c O a, g, <2220><2221><2222><2223><2223> <2220><2221><2222><2223><2223> <2220><2221><2222><2223><2223> <220><221><222><222><223></223> <2220><2221><2222><2223><2223> <2220><2221><2222><2223>

2

0

15

20

variation (1212) OL a,g,c <2220><221><2222><222><223>

variation (1215) or a,g,c <2220><221><2221><2222><223>

variation (1218) or a,g,c <220><221><222><222><223><223>

10

variation (1224) or a,g,c <2220><2221><2222><2223><223>

variation (1236) a,g,c or t <220><221><221><222><222><223>

variation (1239) or a,g,c <2220><221><2222><222><223>

5

4 variation (1242) a,g,c or t variation (1251) ىد variation (1257) variation (1263) a,g,c or t variation (1266) variation (1275) a,g,c or t or or or a,g,c a,g,c a,g,c <220><221><2221><2222><2223></223> <220><221><221><222><222><223> <220><221><222><222><223></223> <220><221><222><222><222><223> <220><221><222><222><222><223> <220><221><221><222><222><223>

5

10

15

20

<220>
<221> variation
<222> (1278)
<222> (1278)
<222> variation
<222> (1281)
<222> (1284)
<222> (1284)
<222> (1284)
<222> (1284)
<222> (1290)
<222> (1290)
<222> (1290)
<222> (1290)
<222> (1290)
<222> (1290)
<222> (1290)
<222> (1290)
<222> (1296)
<222> (1296)
<222> (1296)
<222> (1296)
<222> (1296)
<222> (1296)
<222> (1296)
<222> (1296)
<222> (1296)
<222> (1296)
<222> (1299)
<222> (1299)
<222> (1299)
<222> (1299)
<222> (1299)

variation (1308) variation (1323) variation (1329) a,g,c or t variation (1332) a,g,c or t variation (1338) a,c,g or t variation (1335) a,g,c or t or or a,g,c a,g,c <220><221><221><222><222><223> <220><221> <221> <222> <223> <220><221><222><222><223></223> <220><221><221><222><222><223> <2220><2221><2222><2223><2223> <2220><2221><2222><2223><2223>

15

20

variation (1368) variation (1365) variation (1362) variation (1353) variation (1341) variation or Or or or OL OI (1344)a,g,c a,g,c a,g,c a,g,c a,g,c a,g,c <220><221><221><222><222><223> <2220><2221><2222><2223><2223> <2220><2221><2222><2223><2223> <2220> <221> <2221> <2223> <223> <220><221><221><222><222><223> <220><221><221><222><222><223>

15

10

5

20

=

variation (1371) a, g, c or t variation (1374) variation (1380) variation (1389) a,g,c or t variation (1383) a,g,c or t OK variatic (1386) a,g,c o 0 O U a,g, a,g <2220><221><2221><2222><2223><2223> <2220><2221><2222><2223><2223> <220><221><222><222><222><223> <2220><2221><2222><2223><2223> <2220><2221><2222><2223><2223> <2220><2221><2222><2223><2223>

10 15 20

	ari	1392)	l,g,c or t
<220>	<221> v		<223> a

20

: :

variation (1434) variation (1437) variation (1449) variation (1452) variation (1470) or or or or variatic (1455) 0 O U U g,c U O a, g, 6 6 a, g a, g đ <2220><2221><2222><2223><2223> <2220><2221><2222><2223></2223> <220><221><222><222><222><223> <2220><2221><2222><2223><2223> <220><221><221><222><222><223> <2220><2221><2222><2223><2223>

10

7

20

variation or (1476)a,g,c <220><221><222><222><223><

variation (1479) or a,c,g <2220><2221><2222><2223><2223>

<220>

variation (1482)

or a,g,c <221><222><222><223>

variation (1488) or a,g,c <2220><2221><2222><2223><223>

variation Н 0 (1494)a,g,c <2220><2221><2222><2223><2223>

variation (1497) Or a,g,c <2220><221><222><222><222><223>

5

10

15

25

=

--

variation (1509) variation (1518) variation (1536) a,g,c or t variation (1521) variation (1524) variation or or or or 0 (1506) a,g,c a,g,c a,g,c a,g,c a,g,c <220><221><221><222><222><223> <220><221><222><222><223> <2220><2221><2222><2223><2223> <2220><221><2222><2223><2223> <2220><2221><2222><2223><2223> <2220><2221><2222><2223><2223>

10

15

20

variation (1566) variation or or (1542)a,g,c a,g,c <220><221><221><222><222><223> <220><221><221><222><222><223>

5

variation (1572) a,g,c or t <220><221><222><222><223>

10

variation (1575) or a,g,c <2220><2221><2222><2223><2223>

15

variation (1578) or a,g,c <220><221><221><222><222><223>

20

variation (1581) Or a,g,c <2220><2221><2222><2223><2223>

25

Ţ

<220>
<221> variation
<222> (1584)
<222> a,g,c or t
<220>
<221> variation
<222> (1587)
<222> (1587)

120 240 180 300 360 420 480 540 009 099 ygcnytngcn nytngcngcn nwsnacngay nacnggngay ngtngtnaay ngayggnmgn nathgcntty nytngcnmgn nacnytnwsn ygtnytngar naaygcngay tnmgngcnws cntgywsnca ayccnwsnws ggccntayac cnggnggngt aygtnwsngc cayggnconc arathwsnaa ggccngcnws cngcngcngc cngtnggngg gtnacntgyw snaarcaryt ggnytnathg ytntayytna wsnaaygcna ggnmgnccnt gengtnytnt genttygene ccnmgnatha athgaygtny acncenggnt ngcngcnccn rgcnttymgn ngaygaymgn ngcnaaywsn natgggncar /tngcn nytnccngcn gaaygaytay nmgnacngay rcargtntgg aratg **Nagna** tntaytayyt nytn) thacnwsngc ayggnaaryt tnytnwsngc chgcnytngg gncaywsnyt tnggngaygc cnmgnwsntg thacnggnca cnggnggnga thwsnggnca atggcngtng gcnggnacnc ytngcnytng ytngtngcny ttyggnaaya mgnggnmgng ggngtngcnc atggcnwsny taygtngayg aaygcnggna atggaygtna 10 <400>

5

10

15

20

20

720

1560 1602 1020 1500 1200 1380 1260 1320 ngtncayggn 1140 840 900 960 780 hytnmgntty ymgnwsngay raayaartay nytnttywsn yaaygcnacn nwsntaygtn gytnaayatg ngcnmgnath nytngcnggn gtgggaygay nggngcnwsn nathytncar ngayttygcn ngcnacngay cngtnwsnyt aymgnmgnat tnggmacnyt gncayacnga gnathgtngc tyytngaymg ayaarwsnat tnathacnmg aycarwsnyt cnggnggngg tnttyaargg tngaratgaa tygtntayac tnaaytayga cncayccntg ay tayytngcnm gaygtngcnm gargcnacny carttyggng tgggtnmgnt geneenmgne gtnttygtna gcnwsngtny taygengent tggmgngtnc gaymgnggng gtnttytayg cargarcara aaymgnttyg gayathttya tayccnytna thgtnggncc nytnathgtn ngcnmgnytn aaracn aartgg ggncar gargay cnttycarmg ngaygtngcn rytnggnytn ngarggnwsn cnacnacngt ntaywsnath ycargarytn gnwsnmgnat hgcngaytty nmgngcnmgn yacngaygcn nggnytnggn rmgnytnacn ngcn engenaence nwsn tgygayytng cnggnathca rtay gayccnaarm gnytnytnws nccn ayttyggngc cnaaygayyt ttyggnccna tgwsntaygt cnytnaayaa cngcnccngc cngcngtnga cngtnytngg cnggnttytt cngaycarga tgggtnmgnc ttygtnccnm wsngtngcnc ggnacngaya ytnttygayg gengtngare ggnatgwsng genttywsng ytngcnaaya garmgnaayg gengengeng garggnttyg gargargtng

ggtgacgtgc atggggagat

mays

2ea

11 32 DNA

<400> 11 tgggaattcc <210><211><211><211><212><213> 5

Zea mays 12 33 DNA <2115 <2115 <2125 <2135

10

tgagg atggatttgt gccgtcccac 12 <400>

13 37 DNA Zea <210><211><211><211><212><213></4

cgacggcatg tcggcgg ccatgtggga ctcaacaaat 13 <400>

14 39 DNA Zea <210><211><211><211><212><212><213></ 20

25

mays

Stantator	geracer
***************************************	acatgcaryy
	tctaactaaa
<400> 14	gcggtctaga

15 33 DNA Zea <210><211><211><211><212><212><213>

5

mays

gacgtg tggt catggggaga <400> 15 atgggaattc

16 39 DNA 2ea

10

mays <210><211><211><211><211><212><213></

acat tctaactaaa <400> 16 gcggtctaga

15

mays 17 17 DNA Zea <210><211><211><211><212><212><213>

taccggt <400> 17 ccggttttgg 1

20

18 17 <210><211>

=

17

accaaaa

catgaccggt

18

<400>

mays

2ea

<212><213>

DNA

mays

Zea

19 22 DNA

<210><211><211><211><212><213><213>

10

ပ္ပ

caagcatacc

<400> 19 gacaccattc

15

ដូ

gaaaaatgcc

gttctcacta

20

<400>

mays

Zea

20 22 DNA

<210><211><211><211><212><212><213>

INTERNATIONAL SEARCH REPORT

Intr tional Application No PCT/US 98/15844

IPC 6	ATION OF SUBJECT MATTER C12N15/53 C12N15/82 C12N15/8 C12N1/19 C12N5/10 A01H5/00		/21
According to In	ternational Patent Classification (IPC) or to both national classification	ation and IPC	
B. FIELDS SE	ARCHED		
Minimum docu IPC 6	mentation searched (classification system followed by classification C12N A01H C12Q	on symbols)	
	n searched other than minimum documentation to the extent that a		
Electronic dat	a base consulted during the international search (name of data ba	ase and, where practical, sealers to the sealers to	
C. DOCUME	NTS CONSIDERED TO BE RELEVANT		T
Category *	Citation of document, with indication, where appropriate, of the r	relevant passages	Relevant to claim No.
x	CHEMICAL ABSTRACTS, vol. 119, n 22 November 1993	o. 21,	1-4
	abstract no. 221752, BURCH, L. R. ET AL: "Cytokining and the degradative metabolism cytokinins" XP002086612 see abstract & PHYSIOL. BIOCHEM. CYTOKININS SYMP. (1992), MEETING DATE 1990 EDITOR(S): KAMINEK, MIROSLAV; MI	PLANTS, 0, 29-32. OK, DAVID W. : SPB ACAD.	
·	·		ad in annex.
X Fu	rther documents are listed in the continuation of box C.	Patent family members are list	
"A" documents of the construction of the const	ment defining the general state of the art which is not sidered to be of particular relevance or document but published on or after the international grate ment which may throw doubts on priority claim(s) or ch is cited to establish the publication date of another tion or other special reason (as specified) ament referring to an oral disclosure, use, exhibition or er means ament published prior to the international filing date but or than the priority date claimed	"T" later document published after the or priority date and not in conflict woited to understand the principle of invention "X" document of particular relevance; to cannot be considered novel or call involve an inventive step when the cannot be considered to involve a document of particular relevance; to cannot be considered to involve a document is combined with one of ments, such combination being of in the art. "&" document member of the same particular relevance in the art.	the claimed invention must be considered to adocument is taken alone the claimed invention in inventive step when the or more other such docubirous to a person skilled stent family
Date of t	3 December 1998	Date of mailing of the international 18. 01, 99	n sommi ichoir
Name a	nd mailing address of the ISA European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo ni, Fax: (+31-70) 340-3016	Authorized officer MADDOX, A	

INTERNATIONAL SEARCH REPORT

In ational Application No PCT/US 98/15844

C 10	ation) Documents and the same of the same	PCT/US 98/15844		
C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT				
Category •	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X	SCHREIBER B M N ET AL: "Polyclonal antibodies to maize seedling cytokinin oxidase"	1-4		
·.	ANNUAL MEETING OF THE AMERICAN SOCIETY OF PLANT PHYSIOLOGISTS, CHARLOTTE, NORTH CAROLINA, USA, JULY 29-AUGUST 2, 1995. PLANT PHYSIOLOGY (ROCKVILLE) 108 (2 SUPPL.). 1995. 80., XP002086604			
A	see the whole document	5-24		
X	BURCH, LINDSAY R. ET AL: "The purification of cytokinin oxidase from Zea mays kernals" PHYTOCHEMISTRY (1989), 28(5), 1313-19, XP002086605	1-4		
Υ	see the whole document	5-24		
Υ	MEILAN R ET AL: "Cloning the cytokinin oxidase gene." ANNUAL MEETING OF THE AMERICAN SOCIETY OF	5-24		
	PLANT PHYSIOLOGISTS, PORTLAND, OREGON, USA, JULY 30-AUGUST 3, 1994. PLANT PHYSIOLOGY (ROCKVILLE) 105 (1 SUPPL.). 1994. 68., XP002086606 see the whole document			
	see the whole document			
Y	MIROSLAV KAMINEK: "PROGRESS IN CYTOKININ RESEARCH" TRENDS IN BIOTECHNOLOGY, vol. 10, no. 5, 1 May 1992, pages 159-164, XPO00272384 see page 162	5-24		
P,X	MORRIS, R.O, ET AL.: "Zea mays cytokinin oxidase (ckx1) gene, complete cds" EMBL SEQUENCE ACCESSION NO. AF044603, 27 July 1998, XP002086607 see the whole document	1-11		
A	WANG, J. ET AL: "Cytokinin oxidase purification by affinity chromatography and activation by caffeic acid" PLANT SCI. (SHANNON, IREL.) (1995), 112(2), 161-6, XP002086608 see the whole document	1-24		
A	MOTKYA, V., ET AL.: "Changes in cytokinin content and cytokinin oxidase activity in response to derepression of ipt gene transcripton in transgenic tobacco calli and plants" PLANT PHYSIOLOGY, vol. 112, 1996, pages 1035-1043, XP002086609 see the whole document	1-24		
	-/			

INTERNATIONAL SEARCH REPORT

PUT/US 98/15844

C.(Continua	tion) DOCUMENTS CONSIDERED TO BE RELEVANT		Relevant to claim No.
Category *	Citation of document, with indication, where appropriate, of the relevant passages		Melevant to cialin ivo.
A	·		1-4
A	CRESPI., M., ET AL.: "R. fascians (D188) genes for P450 cytochrome, isopentenyltransferase and ferridoxine" EMBL ACCESSION NO. Z29635, 15 February 1994, XP002086611 see the whole document		5-10
		•	
		•	
			•

REFERENCES

WO0105985. Method to modulate the expression of genes inducing the parthenocarpic trait in plants.

5

10

15

Alberts, B., Bray, D., Lewis, J., Raff, M., Roberts, K., and Watson, J. D. (1994). "Molecular Biology of the Cell." Garland Publishing Inc.

Altschul, S.F., Madden, T.L., Schäffer, A.A., Zhang, J., Zhang, Z., Miller, W. & Lipman, D.J. (1997) "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs." *Nucl. Acids Res.* 25, 3389-3402.

Armstrong, D.J. (1994) in Cytokinins: Chemistry, Activity and Functions, eds. Mok. D.W.S & Mok, M.C. (CRC Boca Raton, FL), pp. 139-154.

An, G., Watson, B. D., Stachel, S., Gordon, M. P., and Nester, E. W. (1985). New cloning vehicles for transformation of higher plants. *EMBO J.* 4, 277-284.

Armstrong, C. L., Petersen, W. P., Buchholz, W. G., Bowen, B. A., and Sulc, S. L. (1990). Factors affecting PEG-mediated stable transformation of maize protoplasts. *Plant Cell Reports* 9, 335-339.

Banerjee, A., Pramanik, A., Bhattacharjya, S., and Balaram, P. (1996). Omega amino acids in peptide design: incorporation into helices. *Biopolymers* 39, 769-777.

Baron, M. H. and Baltimore, D. (1982). Antibodies against the chemically synthesized genome-linked protein of poliovirus react with native virus-specific proteins. *Cell* 28, 395-404.

Bartel, P. L. and Fields, S. (1997). "The Yeast Two-Hybrid System." Oxford University Press.

Benkirane, N., Guichard, G., Briand, J. P., and Muller, S. (1996). Exploration of requirements for peptidomimetic immune recognition. Antigenic and immunogenic properties of reduced peptide bond pseudopeptide analogues of a histone hexapeptide. *J. Biol Chem.* 271, 33218-33224.

.

Berry, A. and Brenner, S. E. (1994). A prototype computer system for de novo protein design. *Biochem.Soc.Trans.* 22, 1033-1036.

Christou, P., McCabe, D. E., and Swain, W. F. (1988). Stable transformation of soybean callus by DNA-coated gold particles. *Plant Physiol.* 87, 671-674.

Crossway, A., Oakes, J. V., Irvine, J. M., Ward, B., Knauf, V. C., and Shewmaker, C. K. (1986). Integration of foreign DNA following microinjection of tobacco mesophyll protoplasts. *Mol. Gen. Genet.* 202, 179-185.

Dale, E. C. and Ow, D. W. (1990). Intra- and intermolecular site-specific recombination in plant cells mediated by bacteriophage P1 recombinase. *Gene* 91, 79-85.

Dodds, J. H. (1985). "Plant genetic engineering." Cambridge University Press.

Doerner, P., Jorgensen, J. E., You, R., Steppuhn, J., and Lamb, C. (1996). Control of root growth and development by cyclin expression. *Nature* 380, 520-523.

Dorner, B., Husar, G. M., Ostresh, J. M., and Houghten, R. A. (1996). The synthesis of peptidomimetic combinatorial libraries through successive amide alkylations. *Bioorg.Med.Chem.* 4, 709-715.

Ellis, J. G., Llewellyn, D. J., Dennis, E. S., and Peacock, W. J. (1987). Maize Adh-1 promoter sequences control anaerobic regulation: addition of upstream promoter elements from constitutive genes is necessary for expression in tobacco.

20 *EMBO J.* **6**, 11-16.

10

Faiss, M., Zalubilová, J., Strnad, M., Schmülling, T. (1997). Conditional transgenic expression of the ipt gene indicates a function for cytokinins in paracrine signaling in whole tobacco plants. *Plant J.* **12**, 401-415.

Fassina, G. and Melli, M. (1994). Identification of interactive sites of proteins and protein receptors by computer-assisted searches for complementary peptide sequences. *Immunomethods*. 5, 114-120.

Fedoroff, N. V. and Smith, D. L. (1993). A versatile system for detecting transposition in Arabidopsis. *Plant J.* 3, 273-289.

Hanahan, D. (1983). Studies on transformation of Escherichia coli with plasmids. J.Mol.Biol 166, 557-580.

Hansen, G. and Chilton, M. D. (1996). "Agrolistic" transformation of plant cells: integration of T-strands generated in planta. *Proc.Natl.Acad.Sci.U.S.A* 93, 14978-14983.

Hansen, G., Shillito, R. D., and Chilton, M. D. (1997). T-strand integration in maize protoplasts after codelivery of a T-DNA substrate and virulence genes.

10 Proc.Natl.Acad.Sci.U.S.A 94, 11726-11730.

Hanson, B., Engler, D., Moy, Y., Newman, B., Ralston, E., and Gutterson, N. (1999). A simple method to enrich an Agrobacterium-transformed population for plants containing only T-DNA sequences. *Plant J.* **19**, 727-734.

Harlow, E. and Lane, D. (1988). "Antibodies: A Laboratory Manual." Cold Spring
Harbor Laboratory Press.

Herrera-Estrella, L., De Block, M., Messens, E. H. J. P., Van Montagu, M., and Schell, J. (1983). Chimeric genes as dominant selectable markers in plant cells. *EMBO J.* 2, 987-995.

Hoffman, D. L., Laiter, S., Singh, R. K., Vaisman, I. I., and Tropsha, A. (1995).

20 Rapid protein structure classification using one-dimensional structure profiles on the bioSCAN parallel computer. *Comput.Appl.Biosci.* 11, 675-679.

Hooykens, P.J.J., Hall, M.A. & Libbeuga, K.R., eds. (1999) Biochemistry and Molecular Biology of Plant Hormones (Elsevier, Amsterdam).

Houba-Heria, N., Pethe, C. d'Alayer, J & Lelouc, M. (1999) Plant J. 17:615-626.

Klee, H.J. & Lanehon, M.B. (1995) in *Plant Hormones: Physiology, Biochemisry and Molecular Biology*, ed. Davies, P.J. (Kluwer, Dordrdrocht, the Netherlands), pp. 340-353.

Krens, F. A., Molendijk, L., Wullems, G. J., and Schilperoort, R. A. (1982). *In vitro* transformation of plant protoplasts with Ti-plasmid DNA. *Nature* 296, 72-74.

Lerner, R. A. (1982). Tapping the immunological repertoire to produce antibodies of predetermined specificity. *Nature* **299**, 593-596.

Lerner, R. A., Green, N., Alexander, H., Liu, F. T., Sutcliffe, J. G., and Shinnick, T. M. (1981). Chemically synthesized peptides predicted from the nucleotide sequence of the hepatitis B virus genome elicit antibodies reactive with the native envelope protein of Dane particles. *Proc.Natl.Acad.Sci.U.S.A* 78, 3403-3407.

Liddle, J. E. and Cryer, A. (1991). "A Practical Guide to Monoclonal Antibodies."

Wiley New York.

Loffler, J., Langui, D., Probst, A., and Huber, G. (1994). Accumulation of a 50 kDa N-terminal fragment of beta-APP695 in Alzheimer's disease hippocampus and neocortex. *Neurochem.Int.* 24, 281-288.

Mok M.C. (1994) in Cytokines: Chemistry, Activity and Function, eds., Mok, D.W.S. & Mok, M.C. (CRC Boca Raton, Fl), pp.155-166.

Monge, A., Lathrop, E. J., Gunn, J. R., Shenkin, P. S., and Friesner, R. A. (1995). Computer modeling of protein folding: conformational and energetic analysis of reduced and detailed protein models. *J.Mol.Biol* 247, 995-1012.

Morris, R.O. et al. (1999). Isolation of a gene encoding a glycosylated cytokinin oxidase from maize. Bioechem. *Biophys. Res. Commun.* 255, 328-333

Motyka, V., Faiss, M., Strnad, M., Kaminek, M. and Schmuelling, T. (1996). Changes in cytokinin content and cytokinin oxidase activity in response to derepression of *ipt* gene transcription in transgenic tobacco calli and plants. *Plant*

25 *Physiol.* **112**, 1035-1043.

· -- · 1--

Murakami, T., Simonds, W. F., and Spiegel, A. M. (1992). Site-specific antibodies directed against G protein beta and gamma subunits: effects on alpha and beta gamma subunit interaction. *Biochemistry* 31, 2905-2911.

Olszewski, K. A., Kolinski, A., and Skolnick, J. (1996). Folding simulations and computer redesign of protein A three-helix bundle motifs. *Proteins* 25, 286-299.

Osborne, B. I., Wirtz, U., and Baker, B. (1995). A system for insertional mutagenesis and chromosomal rearrangement using the Ds transposon and Crelox. *Plant J.* 7, 687-701.

Ostresh, J. M., Blondelle, S. E., Dorner, B., and Houghten, R. A. (1996).

Generation and use of nonsupport-bound peptide and peptidomimetic combinatorial libraries. *Methods Enzymol.* 267, 220-234.

5

Pabo, C. O. and Suchanek, E. G. (1986). Computer-aided model-building strategies for protein design. *Biochemistry* 25, 5987-5991.

Paszkowski, J., Shillito, R. D., Saul, M., Mandak, V., and Hohn, T. H. B. P. I. (1984). Direct gene transfer to plants. *EMBO J.* 3, 2717-2722.

Peralta, E. G., Hellmiss, R., and Ream, W. (1986). Overdrive, a T-DNA transmission enhancer on the A. tumefaciens tumour-inducing plasmid. *EMBO J*. 5, 1137-1142.

Quirino, B.F., Noh, Y.-S., Himelbau, E., and Amasino, R.M. (2000). Molecular aspects of leaf senescence. *Trends in Plant Science* 5, 278-282.

Renouf, D. V. and Hounsell, E. F. (1995). Molecular modelling of glycoproteins by homology with non-glycosylated protein domains, computer simulated glycosylation and molecular dynamics. *Adv. Exp. Med. Biol* 376, 37-45.

Rinaldi, A.C. and Comandini, O. (1999). Cytokinin oxidase strikes again. *Trends*in Plant Sc. 4, 300.

Rose, R. B., Craik, C. S., Douglas, N. L., and Stroud, R. M. (1996). Three-dimensional structures of HIV-1 and SIV protease product complexes. *Biochemistry* 35, 12933-12944.

Rutenber, E. E., McPhee, F., Kaplan, A. P., Gallion, S. L., Hogan, J. C., Jr., Craik, C. S., and Stroud, R. M. (1996). A new class of HIV-1 protease inhibitor: the crystallographic structure, inhibition and chemical synthesis of an aminimide peptide isostere. *Bioorg.Med.Chem.* 4, 1545-1558.

Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989). "Molecular Cloning: A Laboratory Manual." Cold Spring Harbor Laboratory Press.

Schlappi, M., Smith, D., and Fedoroff, N. (1993). TnpA trans-activates methylated maize Suppressor-mutator transposable elements in transgenic tobacco. *Genetics* 133, 1009-1021.

Shioda, T., Andriole, S., Yahata, T., and Isselbacher, K. J. (2000). A green fluorescent protein-reporter mammalian two-hybrid system with

extrachromosomal maintenance of a prey expression plasmid: Application to interaction screening. *Proc.Natl.Acad.Sci.U.S.A* 97, 5220-5224.

Smulling, T., Rupp, H.M. Frank, M& Schafer, S.. (1999) in Advances in Regulation of Plant Growth and Development, eds. Surnad, M. Pac P. & Beck, E. (Peres, Prague), pp. 85-96.


Tamura, R. N., Cooper, H. M., Collo, G., and Quaranta, V. (1991). Cell type-specific integrin variants with alternative alpha chain cytoplasmic domains. *Proc.Natl.Acad.Sci.U.S.A* 88, 10183-10187.

Werner, T., Vadau Motyka, Miroslav Strnad, and Thomas Schmülling (2001) Regulation of plant growth by cytokinin. *Proc. Nat. Acad. Sci.*, 58 (18) 10487-

25 10492.

Van Haaren, M. J., Sedee, N. J., Schilperoort, R. A., and Hooykaas, P. J. (1987).

Overdrive is a T-region transfer enhancer which stimulates T-strand production in Agrobacterium tumefaciens. *Nucleic Acids Res.* 15, 8983-8997.



Van Sluys, M. A., Tempe, J., and Fedoroff, N. (1987). Studies on the introduction and mobility of the maize Activator element in Arabidopsis thaliana and Daucus carota. *EMBO J.* 6, 3881-3889.

Wang, K., Genetello, C., Van Montagu, M., and Zambryski, P. C. (1987).

Sequence context of the T-DNA border repeat element determines its relative activity during T-DNA transfer to plant cells. *Mol.Gen.Genet.* 210, 338-346.

Woulfe, J., Lafortune, L., de Nadai, F., Kitabgi, P., and Beaudet, A. (1994). Post-translational processing of the neurotensin/neuromedin N precursor in the central nervous system of the rat—II. Immunohistochemical localization of maturation products. *Neuroscience* 60, 167-181.

Zhang, Y. L., Dawe, A. L., Jiang, Y., Becker, J. M., and Naider, F. (1996). A superactive peptidomimetic analog of a farnesylated dodecapeptide yeast pheromone. *Biochem.Biophys.Res.Commun.* 224, 327-331.

Annex to Form PCT/ISA/206 COMMUNICATION RELATING TO THE RESULTS OF THE PARTIAL INTERNATIONAL SEARCH

International Application No PCT/EP 01/06833

- 1.The present communication is an Annex to the invitation to pay additional fees (Form PCT/ISA/206). It shows the results of the international search established on the parts of the international application which relate to the invention first mentioned in claims Nos.:
- see 'Invitation to pay additional fees' 2. This communication is not the international search report which will be established according to Article 18 and Rule 43.
- 3.If the applicant does not pay any additional search fees, the information appearing in this communication will be considered as the result of the international search and will be included as such in the international search report.
- 4.If the applicant pays additional fees, the international search report will contain both the information appearing in this communication and the results of the international search on other parts of the international application for which such fees will have been paid.

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 06571 A (UNIV MISSOURI) 11 February 1999 (1999-02-11) cited in the application	1,2
Y	the whole document	7-10, 13-32, 34,35, 39-62
X	ROY O. MORRIS ET AL.,: "Isolation of a gene encoding a glycosylated cytokinin oxidase from maize" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 255, 1999, pages 328-333, XP002151605 cited in the application	3-6,11,
Y	* the whole document, in particular figure 6 *	7-10, 13-32, 34,35, 39-62
X	DATABASE SWALL 'Online! 1 January 1998 (1998-01-01) S.D. ROUNSLEY ET AL.,: XP002151606 Database Accession number ID/AC=022213 abstract	3-6,11,
	-/	

X Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

- "A" document defining the general state of theart which is not considered to be of particular relevance
- "E" earlier document but published on or after theinternational filing date
- "L" document which may throw doubts on priority chim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- 'P' document published prior to the internationalfiling date but fater than the priority date claimed
- "T" later document published after theinternational filing date or priority date and not in conflict with theapplication but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

^{*} Special categories of cited documents :

		·			- ;)
•			•	.7 ♣	•
*		gen. Se			
			· · .		

Annex to Form PCT/ISA/206 COMMUNICATION RELATING TO THE RESULTS OF THE PARTIAL INTERNATIONAL SEARCH

1

International Application No PCT/EP 01/06833

	Citation of document, with indication when a second	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	- Relevant to claim No.
X	DATABASE SWALL 'Online! 1 May 2000 (2000-05-01) M. BEVAN ET AL.,: "Cytokinin oxidase-like protein"	3-6,11, 12
	XP002151607 Database Accession number ID/AC=Q9SU77 abstract	
X	DATABASE SWALL 'Online! 1 May 1999 (1999-05-01) X. LIN ET AL: "Arabidopsis thaliana chromosome II BAC F3P11 genomic sequence. Putative Cytokinin Oxidase" XP002151608 Database Accession number ID/AC=Q9ZUP1 abstract	3-6,11,
X	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; M. FRANK ET AL.,: "TSD genes negatively regulate merismetic activity in Arabidopsis"	11,12
	XP002151616 Database Accession number AN=PREV200000242628 * abstract * & Biologia Plantarum (Prague) 1999, Vol. 42 (Suppl.), page S47	
	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; ZHANG, N. ET AL.,: "Initiation and elongation of lateral roots in Lactuca sativa" XP002151609 Database Accession number AN=PREV199900326622 * abstract * &International J. of Plant Sciences 1999, Vol. 160(3), pages 511-519	1,2, 15-30, 39-62
	- /	
	· · · · · · · · · · · · · · · · · · ·	
		·
	• • •	
		-
		131

	:	

Annex to Form PCT/ISA/206 COMMUNICATION RELATING TO THE RESULTS OF THE PARTIAL INTERNATIONAL SEARCH

International Application No PCT/EP 01/06833

C (Continue	tion) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with Indication, where appropriate, of the relevant passages	Relevant to claim No.	
A	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; Y. KODA ET AL.,: "Cytokinin production by tomato root. Identification of a major cytokinin produced by the root and environmental fcators affecting the production" XP002151610 Database Accession number AN=PREV198988038194 * abstract * & J. of the Faculty of Agriculture Hokkaido University 1989, Vol. 64(1), pages 10-20	1,2, 15-30, 39-62	
•			

 \mathbf{X}

•	

Patent Family Annex

Information on patent family members

International Application No PCT/EP 01/06833

Patent document cited in search report	Publication date	Patent family member(s)		Publication date	
W0 9906571 A	11-02-1999	US AU BR CN EP PL WO HU	6229066 B1 8603898 A 9811592 A 1265146 T 1002096 A1 338330 A1 9906571 A1 0002349 A2	08-05-2001 22-02-1999 19-09-2000 30-08-2000 24-05-2000 23-10-2000 11-02-1999 28-11-2000	

